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ABSTRACT 
 
Rhodococcus equi is a bacterium commonly isolated from soil that primarily 
causes pneumonia in foals and immunocompromised adult horses.  Many vaccines were 
designed and tested to protect foals from developing pneumonia; however, to date, there 
is no vaccine that will protect foals from intrabronchial challenge with R. equi, except 
live, virulent R. equi. To evaluate electron-beam (e-beam) irradiation as a method of 
inactivation of R. equi, 2 concentrations (Concentration 1, 1 × 108 colony-forming 
units/ml [CFU/ml] or Concentration 2, 1 × 109 CFU/ml) of R. equi were submitted to a 
range of e-beam radiation doses, ranging from 0 to 7 kGy. All microorganisms of 
Concentrations 1 and 2 were adequately inactivated by 4 and 5 kGy, respectively, and 
the bacterial cell wall remained intact, whereas heat-inactivated samples indicated a 
compromised cell wall. Both concentrations were tested for immunogenicity and effects 
on fecal microbiome in neonatal foals. Mucosal and serum antibody responses were 
studied, as well as cell-mediated immune responses. Enteral administration of e-beam 
inactivated R. equi increased IFN-γ production and generated naso-pharyngeal  
R. equi-specific IgA in newborn foals. The inactivated vaccine appeared safe and 
immunogenic in neonatal foals in the presence of maternal antibody. No impact of 
treatment on fecal microbiome composition or diversity was observed among vaccinated 
foals; however, marked and significant differences in microbial communities and 
diversity were observed between foals at 32 days of age relative to 2 days of age 
regardless of treatment.  
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In conclusion, electron-beam irradiation is an appropriate method for inactivation 
of R. equi, and e-beam irradiated R. equi vaccine is immunogenic in neonatal foals. Also, 
age-related changes in immune responses and the fecal microbial population occurred in 
healthy foals vaccinated enterally with e-beam inactivated R. equi. Mucosal vaccination 
does not result in major changes of the fecal microbiome in foals. 
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NOMENCLATURE 
 
BAL Broncho-alveolar lavage 
BHI Brain-heart infusion 
BSA Bovine serum albumin 
CBC Complete blood count 
CFU Colony-forming units 
CMI Cell-mediated immunity 
ConA Concanavalin A 
CTB Cholera toxin B 
e-beam Electron-beam 
EBRE 1 Electron-beam inactivated R. equi vaccine dose 1 
EBRE 2 Electron-beam inactivated R. equi vaccine dose 2 
ELISA Enzyme-linked immunosorbent assay 
FET Fisher’s exact test 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
LDA Linear discriminant analysis  
LEfSe linear discriminant analysis effect size 
LVRE Live R. equi group 
MOI Multiplicity of infection 
NA Nuclear area 
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NP Naso-pharyngeal 
OD Optical density 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
RT Room temperature 
TBS  Tris-buffered Saline 
TBST  Tris-buffered Saline 0.005% Tween® 20 
TEM Transmission electron microscopy 
VapA Virulence-associated protein A 
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1 
INTRODUCTION AND LITERATURE REVIEW 
 
R. equi pneumonia 
 
Infectious diseases are leading causes of disease and death in foals, and 
pneumonia is a principal infectious disease of foals.  Respiratory disease was the most 
common cause of disease and death in foals in Texas in 1991, and ranked 3rd as a cause 
of morbidity and 2nd (after a combined category of trauma, injury, and wounds) as a 
cause of mortality in U.S. foals 1 to 6 months of age [1]. Although many organisms 
cause pneumonia in foals, Rhodococcus equi is considered the most common cause of 
severe pneumonia [2-5].  Pneumonia caused by R. equi occurs among foals worldwide 
[5-8]. Rhodococcus equi pneumonia is important to the equine industry for several 
reasons. At affected farms, prevalence and case-fatality rates may be high [9, 10], and 
treatment is generally prolonged, expensive, associated with adverse effects, and not 
uniformly successful [3-5]. Further, currently recommended methods of screening for 
early detection are expensive, labor-intensive, and imperfect [4, 5, 11-14].  Most 
importantly, a highly effective method for prevention, including a vaccine, is lacking for 
this disease despite its global importance. 
Passive immunization of foals with administration of R. equi hyperimmune 
plasma not only has conflicting results regarding efficacy [12, 13, 15-17], but it is an 
expensive and laborious strategy. Ideally, a vaccine would be used to prevent foals from 
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developing pneumonia, but, to date, there is no approved vaccine effective against  
R. equi in spite of the efforts of several laboratories [17-27]. 
The lack of an effective vaccine is likely attributable to the complexity of 
immunity to R. equi [28-30], and the finding that foals appear to be infected very early in 
life [31, 32], when immune responses are naïve or deficient.  It is generally accepted that 
a vaccine will have to be able to provide foals with protection against infection with  
R. equi during early life [33]. Despite all the research done since the first report of  
R. equi causing pneumonia in foals in 1923 [34], fundamental questions of why some 
foals are susceptible, and how to prevent them from developing clinical pneumonia, 
remain unanswered. The only approach that has been demonstrated repeatedly to protect 
foals from intra-bronchial challenge is the administration of live, virulent R. equi [35, 
36]. This strategy, however, is not acceptable because of possible environmental 
contamination with virulent bacteria, potential to cause disease in the host, and 
restrictions and regulations for distributing live vaccines. 
The objectives of the studies in this dissertation were to characterize mucosal and 
serum antibody and cell-mediated immune (CMI) responses, and the effects on fecal 
microbiome of foals receiving intragastrically either: 1) live, virulent R. equi (positive 
control); 2) electron-beam (e-beam) inactivated virulent R. equi with a mucosal 
adjuvant; or, 3) saline solution with a mucosal adjuvant (negative control).  The specific 
aims of the studies were:   
Aim 1) to describe an inactivation method of R. equi using e-beam irradiation; 
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Hypothesis 1) R. equi can be inactivated by e-beam irradiation without losing 
membrane integrity; 
Aim 2) to compare respiratory mucosal and serum antibody responses among 
foals receiving intragastrically either live, virulent R. equi (1×1010 CFUs; positive 
control group), e-beam inactivated R. equi at 2 doses (2×1010 [lower-dose vaccine group; 
EBRE1]   or 1×1011 CFUs [higher-dose vaccine group; EBRE2] combined with a 
mucosal adjuvant), or saline with the mucosal adjuvant (negative control group);  
Hypothesis 2a) enteral administration of live virulent R. equi and e-beam 
inactivated R. equi will produce detectable mucosal and serum antibody responses that 
are significantly greater than saline control foals;  
Hypothesis 2b) mucosal and serum antibody responses will not differ 
significantly between the 2 e-beam vaccine groups or between either vaccine group and 
the foals administered live, virulent R. equi;   
Aim 3) to compare the effects of age and administration of live, virulent R. equi 
and e-beam inactivated R. equi on the fecal microbiome of foals;  
Hypothesis 3) intragastric administration of either dose of e-beam inactivated 
virulent R. equi or live R. equi to foals will not substantively alter the microbiome of 
foals; however, significant age-related changes in the fecal microbiome composition and 
diversity will be detected during the first month of life in foals.   
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Epidemiological considerations 
 
Virtually all foals are exposed to R. equi early in life, but not all are susceptible 
to R. equi pneumonia [37]. Susceptibility to disease cannot be explained by a single 
factor; there must be a balance among 3 key aspects: environment, bacteria and host 
[38]. Each of these elements will be considered in this review of the literature. 
Agent  
Rhodococcus equi is a facultative intracellular bacterium. It is found in grazing 
animals and their environment [5], and the presence of serum antibody is evidence that 
R. equi is widespread among horses [36, 39-41]. Rhodococcus equi can, however, be 
genotypically diverse, and numerous strains of both virulent and avirulent R. equi exist 
[42, 43]. Multiple virulent strains can be associated with infection in foals [44], in fact, a 
few reports show that more than one strain can be found simultaneously causing 
infection in foals [44-46]. In one report, identical strains were found in multiple 
anatomic sites in one infected foal [46]. 
The major route of pulmonary infection reported is the inhalation of dust 
containing R. equi [47]. Once R. equi reaches the lungs, it is phagocytosed, and survives 
and replicates inside the macrophages [6]. Its virulence is related to the ability of the 
organism to resist intracellular killing by macrophages [48], mainly by inhibiting 
phagosome-lysosome fusion [49]. After infecting macrophages, intracellular numbers of 
R. equi increase, reaching macrophage-compromising levels by 48 h [50]. Rhodococcus 
equi isolates that are virulent in foals bear an 85- to 90-kilobase plasmid that encodes for 
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a pathogenicity island, which includes the gene for the virulence-associated protein A 
(vapA); vapA is necessary but not sufficient to cause disease [33, 51-54]. It was 
demonstrated that avirulent, non-plasmid-containing strain failed to replicate in 
macrophages [53], confirming the importance of vapA in disease occurrence. Another 
factor that may influence R. equi fate inside the cell is the way it is taken up by 
macrophages. This process is receptor-mediated, where R. equi binds to macrophages 
primarily via the macrophage complement receptor type 3, Mac-1 (CD11b/CD18), and 
fixes complement by activating the alternative complement pathway [55]. When bacteria 
are opsonized with specific antibodies, however, phagocytosis occurs via Fc receptor 
[56], which enhances R. equi killing by equine macrophages [57]. 
 
Environment  
Rhodococcus equi is commonly found in soil [58] and in equine feces [59-63]. 
Mares shed both avirulent and virulent R. equi in their feces, and therefore, become a 
source of bacteria for the environment of their foal [64]. Even though R. equi is found in 
soil, according to one study, there is not a strong correlation between the presence of 
virulent R. equi in farm soils and the R. equi disease status of those farms [43]. Other 
farm-level risk factors appear to include density of mares and foals, and perhaps foaling 
at pasture [9, 10, 65]. Studies showed that incidence of foals with R. equi pneumonia can 
be expected to be higher at farms with large acreage and greater density of mare and 
foals [9, 10, 65]. 
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Exposure of foals to R. equi in farms is usually high [63-69]. Foals kept in stalls 
were more likely to be exposed to airborne virulent R. equi than those housed in 
paddocks [69]; moreover, foals kept in stalls with dirt floors may be at higher risk for 
developing R. equi pneumonia [70]. This is contributing evidence that the main route of 
pulmonary infection is via inhalation of dust containing R. equi [47]. The lack of 
attention to preventative health practices, however, does not appear to be associated with 
occurrence of R. equi pneumonia [70]. Desirable management practices were 
significantly associated with increased risk of R. equi pneumonia, possibly because of 
closer monitoring of foals for sign of disease [9]. All these observed environmental 
associations are an important source of information and contribute to the knowledge 
about the rhodococcal infection. However, there are both resistant and susceptible foals 
on those farms studied, which reinforces the fact that host-associated factors may be 
more important than environment factors in preventing or controlling R. equi foal 
pneumonia. 
 
Host 
Susceptibility to pneumonia development may also be related to individual 
inability to cope with this organism [40]. Host factors that influence the development of 
pneumonia or clearance of R. equi from lungs are related to the development of an 
appropriate immune response [37]. Foals appear to become naturally infected within the 
first 2 weeks of life [31, 32], when both their innate and adaptive immune systems are 
still developing. Some studies show impairment of bactericidal activity and serum 
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opsonic capacity in foals relative to adult horses [71-73]. Neutrophils from adult horses 
when stimulated with R. equi are a source of proinflammatory cytokines, and this is 
more strongly induced by virulent R. equi than avirulent R. equi [74]. Foal neutrophils 
also increase mRNA expression of many pro-inflammatory cytokines, but this function 
increases with age [75]. In another study, no age-dependent maturation of phagocyte 
function in foals was found, with phagocytic and oxidative burst activity comparable to 
adult horses [76]; however, lower expression of major histocompatibility complex class 
II (MHC-II) has been reported in macrophages and PBMCs from foals compared to adult 
horses [76-78].  
Age-related increases in maturation of adaptive immune responses of foals have 
also been reported in the literature, and include changes in many components of the 
immune system, such as immunoglobulin concentration [76, 79], cytokine production 
[75, 80-82], T-cell subsets [76, 83, 84], as well as ability to respond to inactivated 
vaccines [85]. 
Antibodies alone do not adequately protect foals against experimental infection 
with R. equi [18]. There is evidence, however, that antibodies may influence the immune 
responses to R. equi. Antibodies could block the initial stages of cellular infection, alter 
the route by which bacteria enters the macrophage, and decrease the bacteria’s ability to 
inhibit phagosome-lysosome fusion [37, 42]. Reported associations of specific IgG 
isotypes with protection against R. equi are inconclusive and conflicting. While there is 
evidence that IgG4/7 is the most important isotype in protection against intracellular 
pathogens [86-88], it was suggested that IgG1 (formerly known as IgGa) was expected to 
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be protective because it represented a Th1 isotype, whereas and IgG3/5 and IgG4/7 
(formerly known as IgGb and IgGT, respectively) were Th2 isotypes [89]. Both IgG1 
and IgG4/7 interact with Fc receptors on effector cells and activate complement [88], and 
opsonization with anti-VapA IgG1 significantly enhanced uptake by murine 
macrophages [90].  Subsequent studies, however, have indicated that IgG isotype 
dominance is not indicative of protection against R. equi in foals [35], and may vary with 
breed, age, sex and herd management [79]. IgA is another class of immunoglobulins that 
has been studied in horses, and it is especially important regarding mucosal immunity 
[91-94]. At mucosal surfaces, it functions primarily as a neutralizing antibody, but can 
also opsonize and activate complement [95]. Evidence suggests that equine IgA 
mediated killing through Fc receptors on phagocytes is the strong opsonophagocytic 
activity against S. equi [96], so induction of IgA response in mucosal surfaces may be 
important for adequate opsonization of R. equi for subsequent killing by macrophages. 
Another evidence of the importance of antibodies is the favorable results some studies 
have shown with immunoprophylaxis with hyperimmune plasma [15, 97]. In one study, 
administration of hyperimmune plasma decreased the severity of radiographic lesions 
and prolonged time to increased respiratory effort due to R. equi-induced pneumonia 
[16]. Another study demonstrated that immune plasma conferred protection against 
challenge if administered prior to exposure [17]. The mechanisms of protection remain 
unclear, and theories include the presence of neutralizing antibodies or other non-
specific factors such as complement components and cytokines.[15]. There is 
controversy over the efficacy of hyperimmune plasma administration. A few studies 
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show conflicting results, and failed to demonstrate significant protection against 
challenge [12, 13].  
Cell-mediated immune responses are of irrefutable importance to immunity to 
intracellular pathogens, including R. equi [47, 98]. The 2 major mechanisms by which T 
lymphocytes mediate clearance of intracellular pathogens are secretion of cytokines and 
direct cytotoxicity (usually mediated by MHC class I-restricted CD8+ T lymphocytes) 
[98]. In adult horses, increased numbers of IFN-γ producing CD4+ and CD8+ T cells 
was associated with clearance of virulent R. equi from the lungs after experimental 
infection [99]. The role of IFN-γ in clearance of R. equi was shown in mice with the use 
of anti-IFN-γ monoclonal antibody, where treated mice generated a Th2 response and 
failed to clear the infection and developed pulmonary granulomas [100]. Studies in mice 
have shown that experimental infection with virulent R. equi in immunocompetent 
BALB/c mice generated a Th1 cytokine response and progressively cleared the infection 
[101]. Both CD4+ and CD8+ T cells are important in pulmonary defense against R. equi, 
but clearance is dependent on CD4+ T cells [102]. Not only are foals known to have age-
related impaired ability to produce IFN-γ, [81] [82], essential for activating macrophages 
to kill intracellular R. equi [103], but their CD4+ and CD8+ T cells counts also increase 
with age [76, 84].  Neonatal foals are also deficient in producing other cytokines such as 
IL-4 in response to mitogen stimulation [80, 104, 105].  
Some reports suggest that foals are born immunocompetent. In one study, no 
age-dependent maturation of phagocyte function was observed, and foal cells responded 
with similar phagocytic and oxidative burst activity compared to adult horses [76]. In the 
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same study, the number of immune cells, rather than function, was the limiting factor in 
the immune system of neonatal foals. In one report on the immune responses of foals to 
virulence-associated proteins of R. equi, it was demonstrated that foals are 
immunocompetent, and able to induce recall lymphoproliferation with the same 
magnitude and cytokine phenotype as adult horses, with a strong IFN- γ response [105]. 
Similarly, it has been demonstrated that foals can mount a robust humoral and CMI 
responses to Mycobacterium bovis BCG [106]. The subject of equine neonate 
immunocompetence is controversial, however, there is evidence that their immune 
system can be modulated at an early age, which is of paramount importance in vaccine 
design. 
 
Prevention of R. equi pneumonia  
 
Preventing infectious diseases is generally a more effective approach for control 
than treating affected cases.  Currently, the only methods proven to reduce the incidence 
of R. equi pneumonia at farms are chemoprophylaxis and administration of 
hyperimmune plasma [15, 17, 32]. However, chemoprophylaxis with macrolides is not 
desirable because of concerns of development of microbial resistance [107, 108], and 
also because the approach is not always effective [109]. Transfusion of hyperimmune 
plasma for prevention is expensive, labor-intensive, and not uniformly effective, and 
carries some risk for transfused foals [12, 13, 15, 17, 97].   
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To date, there is no approved vaccine effective against R. equi. A variety of 
vaccine strategies has been evaluated, including immunization of mares [17-21], 
inactivated R. equi administered parenterally to foals or mice [19, 22], sub-unit vaccines 
[20, 21, 23], DNA vaccines [24, 25], and live, mutant vaccines [26, 27]. Vaccines that 
may be protective against experimental infection in mice are not effective in foals [23-
25, 90, 110]. These discrepant results may be explained in part because there is no 
mouse (or other laboratory animal) model of pneumonia caused by R. equi: mouse 
models of R. equi infection measure concentrations in tissues (primarily liver and spleen) 
following intravenous or intraperitoneal infection with R. equi.  Hence, the lack of an 
effective vaccine is attributable to the complexity of immunity to R. equi [28-30], and 
also that foals appear to be infected early in life [31, 32], at an age when immune 
responses are not fully developed. 
Despite the success of oral administration of live organisms to protect foals 
against experimental challenge [35, 36], very limited information is available regarding 
immune and other biological responses to the enteral route of vaccination. Oral 
vaccination of foals with a live attenuated mutant strain of R. equi protected 2 out of 4 
foals from developing pyogranulomatous pneumonia after intratracheal challenge [111]. 
Traditional approaches of parenteral vaccination generally do not provide strong 
protection against mucosal infections [112, 113].  Protective responses induced by oral 
vaccination against other respiratory pathogens have also been documented in mice 
[114-116]. One major limitation of the cited studies of oral vaccination of foals is that 
evaluation of immune responses to R. equi antigens has been limited to serum antibody 
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responses; mucosal antibodies and CMI responses have not been systematically 
evaluated.   
Despite demonstrated efficacy, the use of live organisms for mucosal vaccines 
has important drawbacks.  The use of live, virulent R. equi in foals is not generally 
acceptable because of the potential to cause disease in the host, even when reduced-
virulence mutant strains are used [27].  Moreover, there are societal and regulatory 
concerns for environmental contamination with virulent bacteria or genetically modified 
bacteria.  The manufacturing and distribution of live vaccines also can be restrictive. To 
circumvent limitations of use of live, replicating virulent bacteria as a vaccine, we 
propose to use e-beam irradiation to inactivate R. equi while causing minimal structural 
damage in hopes of eliciting immune responses in neonatal foals following enteral 
administration similar to those generated by live organisms. 
 
Electron-beam inactivation of bacteria  
 
Electron-beam irradiation is a technology for microbial inactivation that currently 
is used for sterilization and pasteurization [117-120], and at appropriate doses can be 
used to inactivate large volumes of microbial cultures or to sterilize materials [121-123]. 
Bacterial survival is inversely related to e-beam irradiation dose, as reported for 
Escherichia coli K-12 [124], Bacillus atrophaeus [125], and avian influenza virus [123]. 
Ionizing radiation inactivates microorganisms by directly causing breaks in DNA strands 
or indirectly by the generation of radiolytic byproducts that interact with DNA causing 
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breakages. At doses that are used to inactivate microorganisms, the numbers of such 
DNA strand-breaks are so numerous and extensive that the cell’s DNA repair 
mechanisms cannot cope with the extent of damage such that the cells become 
inactivated [126].  
Electron-beam inactivation has advantages relative to inactivating bacteria using 
heat or formalin.  Heat inactivation is known to denature proteins, including 
immunogenic epitopes on the cell surface [127].  Formalin also alters immunogenic 
epitopes [128]. More importantly, formalin is widely recognized as resulting in 
incomplete inactivation of organisms, and has been associated with vaccine-associated 
disease resulting from inadequate inactivation [129]. In contrast, e-beam inactivation is 
highly reliable. Moreover, e-beam inactivation can be titrated such that there is no 
structural damage to cell walls and membranes, including surface antigens: the bacteria 
are rendered replication-incompetent and metabolically inactive, but the cell structure is 
maintained (Pillai, 2012, personal communication). Preservation of the cell wall integrity 
after e-beam irradiation has also been shown for Paracoccidioides brasiliensis [130], 
and membrane damage of Bacillus spp. spores was observed only after high doses of  
e-beam irradiation [131]. 
 
Cholera toxin B as mucosal adjuvant 
 
Inactivated vaccines generally require an adjuvant to enhance immune responses 
[132].  Cholera toxin B (CTB) produced by Vibrio cholerae is a strong mucosal 
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adjuvant. It binds avidly to receptors on the intestinal mucosal surface, is resistant to 
degradation by intestinal proteolytic enzymes [133], and stimulates antigen-specific 
mucosal immunity and dendritic cell maturation with synthesis of costimulatory factors 
and secretion of inflammatory cytokines and chemokines [134]. In mice vaccinated 
against H5N1 influenza, CTB has been shown to induce serum IgG, mucosal IgA, and 
CMI responses [135], and to protect against lethal infection [136]. Both A and B 
subunits of CTB may promote capture of pathogens by dendritic cells in Peyer’s patches 
[137].  
 
Microbiome 
 
An important safety consideration for administration of live or inactivated 
bacteria for enteral vaccination is the impact that it might have on the intestinal 
microbiome.  Although there are a few reports of intestinal microbiome in adult horses 
[138-143], the intestinal microbiome has not been systematically evaluated in neonatal 
foals [144]. The resident intestinal or fecal microbiota has been described for neonates of 
other species, such as cats [145, 146], dogs [147], and humans [148-151], and evidence 
exists that the intestinal microbiome of neonates develops with age [148-150], and is 
linked to the functional development of the gut and gut immunity [148-150, 152, 153]. 
In humans, the initial microbes colonizing infants are facultative anaerobic bacteria, such 
as E. coli and Streptococcus spp. [154]. In puppies and kittens, the sterile gastro-
intestinal tract is presumably colonized by bacteria present in the birth canal and from 
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the environment [155], and human neonates appear to become colonized by these 
sources as well as through the intestinal microbiota of the mother [148, 154]. One of the 
challenges of studying the microbiome in horses is the complexity of the gastro-
intestinal tract. The microbial population of adult horse fecal samples is likely to 
represent that of the right dorsal colon, but not that of the cecum [156]. In one study, 
rectal samples were not entirely representative of intestinal compartments in the small or 
large intestine [143]. This represents one limitation in the study of microbiome in horses, 
where most samples are fecal samples.   To our knowledge, the impact of enteral 
vaccination on the intestinal or fecal microbiome of neonates of domesticated animals 
has not been evaluated. 
In summary, there is a lot of controversy regarding foal’s immune responses to  
R. equi. The correlates of protection against R. equi pneumonia are also unknown, which 
imposes difficulty to design vaccines that will generate the appropriate immune 
responses necessary to protect foals from naturally or induced exposure to R. equi. We 
aim, with the studies presented in this dissertation, to characterize mucosal and serum 
antibody and cell-mediated immune responses to enterally administrated both live and  
e-beam irradiated R. equi, and their effects on fecal microbiome of foals. The results 
presented here will help to elucidate more aspects of the immune response of foals to 
this bacterium, as well as generate a candidate vaccine for potential use in foals in 
affected farms.   
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IMMUNOGENICITY OF AN ELECTRON-BEAM IRRADIATED  
RHODOCOCCUS EQUI VACCINE 
 
Introduction 
 
Rhodococcus equi is a facultative intracellular pathogen recognized clinically as 
a leading cause of severe pneumonia in foals [5, 7, 8, 98]. To date, an efficacious 
vaccine against R. equi for foals is lacking and there is no approved vaccine for foals 
against R. equi in North America. Although a variety of strategies have been evaluated 
for vaccination against R. equi (including immunization of mares [17-21], inactivated  
R. equi administered parenterally to foals or mice [19, 22], sub-unit vaccines [20, 21, 
23], DNA vaccines [24, 25], and live, mutant vaccines [26, 27]), oral administration of 
live, virulent R. equi is the only vaccination strategy that has been demonstrated 
repeatedly to protect foals against experimental intrabronchial challenge with virulent R. 
equi [35, 36, 157]. However, the administration of live, virulent organisms is not 
considered an acceptable strategy for vaccination of foals at horse breeding farms 
because of concerns for environmental dissemination and the potential to cause disease 
in some foals.   
Inactivated bacteria and viruses can elicit protective immune responses against 
systemic infections, including those of the respiratory tract [158-161]. Electron-beam 
irradiation is a technology for microbial inactivation that is currently used for 
sterilization and pasteurization [117-120]. Electron-beam irradiation at appropriate doses 
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can be used to inactivate large volumes of microbial cultures or to sterilize materials 
such as medical devices [121-123]. Electron-beam inactivation has advantages relative 
to inactivating bacteria using heat or formalin.  Inactivation with either heat or formalin 
is known to denature proteins, including immunogenic epitopes on the cell surface [127, 
128]. More importantly, formalin is widely recognized as resulting in incomplete 
inactivation of organisms, and has been associated with vaccine-associated disease 
resulting from inadequate inactivation [129]. Thus, there is need for a reliable method of 
microbial inactivation that will retain the bacterial cell structure as similar as possible to 
a live organism for use in producing vaccines. We therefore identified a dose of e-beam 
irradiation that would inhibit bacterial replication while maintaining outer membrane 
integrity of R. equi, and examined the immunogenicity of R. equi inactivated accordingly 
when administered enterally to newborn foals.  
 
Material and methods 
 
Ethics statement 
All procedures for this study were reviewed and approved by the Texas A&M 
University Institutional Animal Care and Use Committee (protocol number AUP# 2011-
124) and the Texas A&M University Institutional Biosafety Committee (permit number 
20110183-Cohen). The foals used in this study are owned by Texas A&M University, 
and permission for their use was provided in compliance with the Institutional Animal 
Care and Use Committee procedures. 
  
 
18 
Preparation of bacteria and electron-beam irradiation   
Rhodococcus equi strain EIDL 5-331 (a virulent isolate from a Texas foal) was 
used for this study.  One colony-forming unit (CFU) was inoculated into 50 ml of brain-
heart infusion (BHI) broth and shaken for 24 h at 37oC, sub-cultured in 1000 ml of BHI 
broth and shaken for 24 h at 37oC. The bacterial suspension was centrifuged at 3400 × g 
(5810R, Eppendorf AG, Hamburg, Germany) for 20 min at 4oC, the supernatant 
discarded, and the pellets washed with 100 ml of phosphate-buffered saline (PBS), using 
the same centrifugation protocol (described in Appendix A). The supernatant was 
discarded, the bacteria were resuspended in sterile 0.9% NaCl solution, and the 
concentration of bacteria was determined spectrophotometrically (Genesys™ 20, 
Thermo Scientific, Waltham, MA, USA). For the e-beam dose identification experiment, 
25 ml of bacterial suspensions of either approximately 1 × 108 (concentration 1) or  
1 × 109 CFU/ml (concentration 2) were double-bagged in heat-sealed sacs with no 
headspace, sealed inside a 95-kPa transport bag (Therapak, Duarte, CA, USA; standard 
operating procedure in Appendix B, package pictures on Appendix C), and exposed to 
irradiation doses ranging from 0 to 7 kGy (in integer-unit doses) using a 10-MeV, 18-
kW linear accelerator. Alanine dosimeters were used to verify the delivered e-beam 
dose. The interaction of ionizing radiation with alanine releases free radicals [162], 
which were detected by an alanine dosimeter reader (E-scan, Bruker BioSpin, Corp., 
Billerica, MA, USA). Twenty-five ml of non-irradiated bacteria were inactivated for 30 
min in a water bath at 85oC, and were used as the heat-inactivated negative control. After 
irradiation, quantitative culture was performed to determine concentration of replicating 
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R. equi in each irradiated sample, and to calculate the D10-value. Experiments were 
conducted in triplicates, performed on 3 different days. For vaccine preparations 
administered to foals, e-beam irradiated R. equi were cultured on days 1, 3, 5, 7, and 14 
post-irradiation to confirm absence of bacterial replication. 
 
Cell wall integrity of irradiated R. equi 
The immunogenic proteins of R. equi are expressed in the surface of the 
bacterium [163], therefore, keeping the cell wall integrity is important for maintaining 
the immunogenicity of the vaccine. Bacteria were grown as described above, and e-beam 
irradiated at the minimum dose that effectively inactivated all microorganisms for each 
concentration; live and heat-inactivated R. equi were prepared as positive and negative 
controls, respectively. Samples were kept at 4oC for 12 h, and 1, 2, and 4 weeks after 
either irradiation or heat-inactivation. Two methods were used to determine whether the 
bacterial cell wall was intact.  The first was a fluorescence-based assay (LIVE/DEAD® 
BacLight™ bacterial viability kit, Molecular Probes, Inc., Eugene, OR, USA; see 
Appendix D for protocol), which utilizes a mixture of SYTO® 9 green-fluorescent 
nucleic acid stain (which stains all bacteria) and propidium iodide (which only 
penetrates damaged membranes) [164], which was used according to the manufacturer’s 
instructions using a microplate reader (Synergy 2, Biotek, Winooski, VT, USA).  The 
second method was transmission electron microscopy (TEM) of irradiated samples, heat-
inactivated, and live R. equi at 12 h, and 1, 2, or 4 weeks after processing. Bacterial cells 
were fixed with 2% glutaraldehyde, 3% formaldehyde in 0.1 M sodium cacodylate 
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buffer, then post-fixed with 1% osmium tetroxide and 0.5% potassium ferrocyanide, 
dehydrated in an ascending alcohol series, and embedded in epoxy resin. Ultrathin 
sections of the cells were examined with an FEI Morgagni 268 transmission electron 
microscope at an accelerating voltage of 80 kV. Digital images were acquired with a 
MegaView III camera operated with iTEM software (Olympus Soft Imaging Systems, 
Germany), then post-processed with Adobe Photoshop (see Appendix S for a full paper 
on development of an R. equi vaccine using e-beam irradiation).  
 
Study animals 
Thirty-four healthy Quarter Horse foals were used for this study. All foals had 
age-appropriate results of complete blood count (CBC) on day 2 of life, and had 
adequate transfer of passive immunity as assessed by a commercially-available 
qualitative immunoassay for serum concentration of total immunoglobulin G (IgG; 
SNAP test; IDEXX, Inc., Westbrook, ME, USA). All foals were monitored daily by 
technical staff and twice weekly by a veterinarian and remained in good health without 
clinical signs of disease throughout the study. Individual foals were randomly assigned 
to the following groups: 1) EBRE 1 group (n=9) which received 2×1010 CFUs of R. equi 
inactivated by 4 kGy of e-beam radiation  in 100 ml of saline adjuvanted with 100 µg of 
cholera toxin B subunit (CTB, List Biological Laboratories, Campbell, CA, USA); 2) 
EBRE 2 group (n=10) which received 1×1011 CFUs of R. equi inactivated by 5 kGy of 
e-beam radiation in 100 ml of saline adjuvanted with 100 µg of CTB; 3) Saline 
(negative) control group (n=9) which received 100 ml of saline adjuvanted with 100 µg 
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of CTB; and, 4) LVRE (positive) control group (n=6) which received 1×1010 CFUs of 
live R. equi in 100 ml of saline.  All treatments (including live R. equi) were 
administered enterally with a nasogastric tube on days 2, 9, 16, and 23 of life, 
administration route, perinatal period and frequency that have been demonstrated to 
protect foals against intrabronchial challenge when using live R. equi [35, 36]. 
Furthermore, intragastric route is better tolerated by foals than intranasal route, and it is 
more accepted by foals’ owners. Physiological saline (NaCl 0.9%) was used as a diluent 
for e-beam vaccines, live bacteria, and the negative control. The doses for irradiating 
both preparations of vaccine were identified on previous experiments (see section 
“Preparation of bacteria and electron-beam irradiation” and “Cell wall integrity of 
irradiated R. equi”). The dose of 100 µg of CTB was has been shown previously to be 
safe and to induce local antibody production in horses [165]. 
Serum and milk samples from the respective mares were collected on day 2 of 
foals’ life for assessment of maternal antibodies. All mares and foals are naturally 
exposed to R. equi from the environment [63], therefore, a considerable level of antibody 
response is expected from the tested mares and foals, and likely represents natural 
exposure. 
 
Sample collection  
Samples were collected on day 2 (prior to vaccination; birth day was considered 
day 1) and on day 32 of life. For the bronchoalveolar lavage (BAL) procedure, a 3-meter 
endoscope disinfected with glutaraldehyde prior to use was passed via the nose into the 
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lungs, until the tube became gently lodged in a bronchus.  Sterile saline (30 ml) was 
instilled into the lung via the scope’s infusion channel, followed by 20 ml of air to flush, 
and immediately aspirated to recover a minimum volume of 15 ml of fluid.   
Naso-pharyngeal samples were collected by inserting a 16-inch cotton swab pre-
moistened with 3 ml of sterile saline in the nasal ventral meatus. The naso-pharyngeal 
area was swabbed, the liquid was manually squeezed from the swab using a 60-ml 
syringe into a tube, and samples were frozen at -80oC until assayed. 
Blood was collected from a jugular vein into tubes; 5 ml of blood was collected 
into a tube without anticoagulant and centrifuged at 3000 ×g for 5 min to harvest serum 
which was separated and frozen at -80oC until assayed, and 16 ml of blood was collected 
into tubes with sodium heparin as an anticoagulant for isolation of peripheral blood 
mononuclear cells (PBMCs; protocol in Appendix E), constituted mostly of T 
lymphocytes (CD4+ and CD8+ T cells), followed by B lymphocytes and a smaller 
number of monocytes [76, 166].  
 
Cell-mediated immune response 
The CMI response to vaccination was assessed by IFN-γ production by PBMCs 
following specific stimulation with e-beam inactivated R. equi. Peripheral blood 
mononuclear cells were isolated using Ficoll-Paque™ (GE Healthcare, Piscataway, NJ, 
USA) gradient separation, and carbonyl iron (Sigma-Aldrich, St. Louis, MO, USA) 
magnetic separation was performed to completely remove neutrophils from the PBMC 
suspension [167]. Cells were resuspended in RPMI-1640 media (Gibco®, Life 
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Technologies, Grand Island, NY, USA) with 15% fetal bovine serum (Gibco®, Life 
Technologies, Grand Island, NY, USA) and 1.5% penicillin-streptomycin (Gibco®, Life 
Technologies, Grand Island, NY, USA). Each well of a 24-well plate received 1 ml 
containing 1 × 106 cells, which were cultured for 48 h at 37oC with 5% CO2 with either 
media only, the mitogen ConA (positive control; 5 µg/ml, Sigma-Aldrich, St. Louis, 
MO, USA), or e-beam inactivated R. equi (multiplicity of infection of 1:10). The interval 
of 48 h was chosen to provide enough time for antigen-presentation to T cells in culture. 
The supernatants from each group were harvested, centrifuged at 300 ×g, and 
frozen at -80oC until examined for IFN-γ production using an equine IFN-γ ELISA kit 
(Mabtech Inc., Mariemont, Ohio, USA) according to manufacturer’s instructions 
(protocol on Appendix F). Optical densities were determined using a microplate reader, 
standard curves were generated, and IFN-γ concentrations in each sample were 
calculated using Gen 5 software. 
 
Mucosal and serum antibody responses 
Mucosal humoral immune responses were assessed by quantifying total and  
R. equi-specific IgA and IgG isotypes IgG1, IgG3/5, and IgG4/7 in BAL fluid, and total 
and R. equi-specific IgA in naso-pharyngeal swab eluates. Serum antibody response was 
assessed by quantifying total and R. equi-specific IgA and IgG isotypes (IgG1, IgG4/7, 
IgG3/5) concentrations in serum of vaccinated foals. 
Concentrations of total IgA and IgG isotypes (IgG1, IgG3/5, and IgG4/7) were 
determined by ELISA using a commercial kit (Bethyl Laboratories, Montgomery, TX, 
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USA) according to manufacturer’s instructions (protocol on Appendix G). Reference 
serum (Bethyl Laboratories, Montgomery, TX, USA) was added for the positive 
controls, and to establish standard curves, and dilution buffer was used as blank. Optical 
densities (ODs) were determined by using a microplate reader Synergy 2 (Biotek, 
Winooski, VT, USA). Standard curves were generated and immunoglobulin 
concentrations in each sample were calculated for each isotype using Gen 5 software 
(Biotek, Winooski, VT, USA). 
For determination of R. equi-specific IgA and IgG isotypes, we used a protocol 
described previously [86] (Appendix H). Briefly, ELISA plates (Maxisorp, Nalge Nunc 
International, Rochester, NY) were coated with 2.5 µg/ml of R. equi antigen diluted in 
coating buffer (Carbonate-bicarbonate buffer, Sigma-Aldrich, St. Louis, MO) overnight 
at 4oC. The protocol for preparation of R. equi antigen has been described previously 
[87] (Appendix I), except R. equi virulent field strain 5-331 was used in this study. The 
antigen was produced by inoculating blood agar plates with R. equi strain 5-331 and 
incubating at 37oC for 48 hours. One colony from this pure culture was selected and 
used to inoculate 500 ml of BHI broth. The flask with inoculated broth will be placed on 
a shaker for 24 h at 37oC, and then centrifuged at 3400 × g for 10 min to pellet the 
bacteria. The supernatant was discarded and the pellet resuspended in 200 ml of PBS, 
then centrifuged again at 3400 × g for 10 min and the pellet resuspended in 10 ml of 
PBS. Three freeze/thaw cycles were done by freezing at -80oC and thawing in 37oC. 
After the last thawing cycle, the suspension was centrifuged at 12,000 × g for 15 min at 
4oC, the pellet discarded and the supernatant saved and centrifuged again at 14000 × g 
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for 35 min at 4oC. The suspension was tested for protein concentration using a BCA kit 
according to manufacturer’s instructions (Thermo Fisher Scientific Inc., Rockford, 
IL).Plates were washed as described above, blocked with 200 µl TBS 1% BSA for 30 
min at room temperature (RT), and washed again. Two-fold serial dilutions of serum 
samples from study foals, positive control R. equi hyperimmune plasma (Mg Biologics, 
Ames, IA), and negative control fetal horse serum (Biowest, Miami, FL, USA) were 
added in duplicates to the wells and incubated for 60 min at 22oC. Both BAL fluid and 
NP swab eluates were used undiluted. After another washing, goat anti-horse IgA, IgG1, 
and IgG3/5 peroxidase conjugated, and sheep anti-Horse IgG4/7 peroxidase conjugated 
(Bethyl Laboratories, Montgomery, TX) were added to the wells and incubated for 60 
min at RT. Plates were washed again, and TMB One Component HRP Microwell 
Substrate (Bethyl Laboratories, Montgomery, TX) was added to the wells and incubated 
for 15 min at RT in the dark. The reaction was stopped by adding stop solution to the 
wells. Optical densities were determined by using a microplate reader. Relative 
quantities for day 2 and day 32 samples were obtained by using the following formula: 
 
 
 
 
 
 
 
The ratio of the relative quantities on day 32 to the relative quantities on day 2 
was used to describe the relative increase/decrease of antibodies following vaccination.  
Relative quantities = OD sample - OD negative controlOD positive control  - OD negative control  
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When determining concentration of total immunoglobulins in BAL fluid, a urea-
dilution method [168] was used to estimate the volume of pulmonary epithelial lining 
fluid:concentrations of BAL fluid IgG and IgA titers and to account for differences in 
recovery of BAL fluid.  
 
Data analysis  
All analyses were conducted using S-PLUS (Version 8.0; Insightful, Inc.) and R 
(Version 2.12.1; R Statistical Project) and a significance level of P < 0.05. Analysis of 
growth curves and cell wall integrity fluorescence data were performed using linear 
mixed-effects models with experimental replicates modeled as random effects [169]. The 
D10-value was calculated from the negative inverse of the slope from the linear mixed-
effects regression of the irradiation dose on the logarithm10 of the microbial population 
[170]. Transmission electron microscopy data were descriptive only.  
Foal data were analyzed using the ratio of relative quantities on day 32 to relative 
quantities on day 2 of life (baseline) of immunoglobulins or IFN-γ concentrations, or 
using the proportion of foals that had an increase in these relative quantities. This 
approach was used because of considerable inter-individual variation among animals 
irrespective of treatment group. Even though the ratio of day 32 relative to day 2 was 
used for statistical analysis, the primary data from both days 2 and 32 of life are 
presented in the Appendices J (IFN-γ), K (serum antibody), L (NP antibodies) and M 
(BAL fluid antibodies). To adjust for the skewness of the data, log10-transformation was 
used to ensure they met the assumptions underlying the modeling strategy. Ratio data 
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were analyzed using a generalized linear model with concentrations as the outcome 
variable and study group as the independent variable of interest. Model fit was assessed 
by examining diagnostic plots of residuals.  Post-hoc pair-wise comparisons among 
groups were made using the method of Sidak [171].  Proportions of foals with increased 
immunoglobulin isotypes were compared among groups using Fisher’s exact test. 
Association (correlation) between immunoglobulin concentration in mare serum 
and milk immunoglobulins, and mare milk and NP swab eluates IgA were made using 
linear regression analysis. Comparisons of immunoglobulin concentrations among 
treatment groups were performed using Kruskal-Wallis testing.  
 
Results 
 
Effects of e-beam irradiation on R. equi  
The doses required to prevent replication of R. equi at concentrations of 1 × 108 
and 1 × 109 CFU/ml were 4 and 5 kGy, respectively (Fig. 1).  The D10-values estimated 
for R. equi strain 5-331 in 0.9% NaCl exposed to 10-MeV, 18-kW e-beam irradiation for 
the 2 concentrations were similar (0.48 [0.37 to 0.69] and 0.53 [0.47 to 0.61]), 
approximately 0.505 kGy) and did not differ significantly (P>0.05).  
The green/red fluorescence ratio increased significantly (P < 0.05) with the 
addition of intact bacteria in all groups except the heat-inactivated group (Fig. 2A, B, C 
and D), indicating that e-beam irradiation did not damage bacterial membrane integrity 
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but that heat-inactivation did.  Using TEM, the overall integrity of the outer bacterial cell 
wall of all treated groups was preserved (Fig. 3A, B, C, and D).  
 
 
 
 
Fig. 1. Survival curves of electron-beam irradiated R. equi. Survival curves for R. equi samples 
resuspended in 0.9% NaCl irradiated with e-beam doses ranging from 0 to 7 kGy. Survival curve for 
Concentration 1 (1 × 108 CFU/ml) is indicated by the symbol ○; Survival curve for Concentration 2  
(1 × 109 CFU/ml) is indicated by the symbol ×; *0 represents true 0 and not 100 = 1.  
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Fig. 2. Ratio of green/red fluorescence of e-beam irradiated R. equi. Fluorescence-based LIVE/DEAD 
BacLight bacterial viability kit for Concentration 1 (approximately 1 × 108 colony-forming CFU/ml; 
square) and Concentration 2 (approximately 1 × 109 CFU/ml; triangle) e-beam irradiated, live (diamond 
shape) and heat-inactivated samples (circle). A) Day 1, B) Week 1, C) Week 2, and D) Week 4 of storage 
at 4oC. Error bars are symmetric, but only plus bar is shown. 
 
 
 
 
 
A B 
C D 
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Fig. 3 Ultrastructure of live, heat-inactivated, and e-beam irradiated R. equi. a) Live group, week 4. 
Normal morphologic appearance of the nuclear area (NA). b) Concentration 2 e-beam irradiated, week 4. 
Similar morphologic appearance of the NA compared to the live bacterium of image “a”.  The arrows are 
indicating invaginations of the layered cell wall.  c) Heat-inactivated group, day 1. Nuclear area (NA) 
markedly vacuolated and has increased electron lucency. d) Live group, day 1. Closer magnification of a 
live bacterium depicting the localization of the layered cell wall (black arrows) and of glycogen-like 
material (white arrowheads).  e) Concentration 2 e-beam irradiated with 5 kGy, day 1. Closer view of 
radiated bacteria demonstrating intact layered cell walls (black arrowheads), invaginations of the layered 
wall (arrow), and preservation of glycogen-like material (white arrowheads). f) Heat-inactivated, day 1. 
Closer magnification of a heat-killed bacterium that presents large areas where the layered cell wall is 
either not present (arrows) or presents marked invagination/coiling (arrowheads). Note the vacuolated 
nuclear area (*), and inconspicuous glycogen-like material. Concentration 2 (b) and Live bacteria (a) 
remains intact after 4 weeks of refrigeration, whereas heat-inactivated (c) bacteria denote changes after 12 
h of refrigeration. 
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Changes affecting the wall were confined to the layered cell wall (LCW) of all 
groups, and were more severe among bacteria of heat-inactivated groups suggesting a 
more severe compromise of the cell wall integrity (consistent with the fluorescent-based 
results).  The internal cell contents were only morphologically affected in bacteria of the 
heat-inactivated group.  Noticeable changes included enlarged nuclear areas that were 
admixed with a filamentous material and inconspicuous glycogen-like deposits (Fig. 
3D). The antigenicity of the e-beam irradiated R. equi was demonstrated by western blot 
(data not shown) using an anti-vapA antibody (kindly provided by Dr. Shinji Takai). 
 
Cell-mediated immune response 
Stimulation with ConA significantly (P < 0.05) stimulated IFN-γ production in 
cultured PBMCs on both days 2 and 32 relative to unstimulated cells, and stimulation 
with R. equi resulted in significantly greater IFN-γ production on day 32 (P < 0.05) 
relative to unstimulated control (media only; Fig. 4). The IFN-γ response was 
significantly (P < 0.05) greater for foals in the LVRE, EBRE 1, and EBRE 2 groups than 
for foals in the saline control group (Fig. 5).  
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Fig. 4. Effects of stimulus on IFN-γ production in cultured PBMCs of foals. Effects of stimulus 
(Concavalin A 5 µg/ml, e-beam irradiated R. equi MOI 1:10, or saline [unstimulated control]) on 
concentration of IFN-γ in cell culture supernatant of foals at ages 2 days (panel a.) or 31 days (panel b.), 
by treatment group.  At both ages, Concavalin A stimulated a significant increase in IFN-g concentration.  
Within a panel, differing letters indicate significant differences among groups.  Between panels, different 
numbers indicate differences between ages. 
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Fig. 5. Mean ratio of IFN-γ concentration in supernatant of cultured PBMCs. Relative quantities on day 32 
relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups: 1) Saline: enteral adjuvant only 
controls (N = 9); 2) EBRE 1: foals receiving 1 x 1011 R. equi e-beam irradiated with 4 kGy enterally  
(N = 10); 3) EBRE 2: foals receiving 2 x 1010 R. equi e-beam irradiated with 5 kGy enterally (N = 9); and, 
4) LVRE: foals receiving 1 x 1010 live, virulent R. equi enterally (N = 6). Symbols with differing letters 
indicate significant (P < 0.05) differences among groups.  
 
 
 
 
Serum antibody immunity 
Serum concentrations of total IgA, IgG4/7, and IgG3/5 decreased significantly with 
age for foals in all groups (Fig. 6); however, there were no significant differences in the 
decline of total immunoglobulins among groups.  
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Fig. 6. Mean ratio of total IgA and IgG isotypes concentration from foal serum. Concentration on day 32 
relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups: 1) Saline: enteral adjuvant only 
controls (N = 9); 2) EBRE 1: foals receiving 1 x 1011 R. equi e-beam irradiated with 4 kGy enterally (N = 
10); 3) EBRE 2: foals receiving 2 x 1010 R. equi e-beam irradiated with 5 kGy enterally (N = 9); and, 4) 
LVRE: foals receiving 1 x 1010 live, virulent R. equi enterally (N = 6); Bars with differing letters indicate 
significant (P < 0.05) differences among groups. A) Total IgA; B) Total IgG1; C) Total IgG4/7; D) Total 
IgG3/5.  
 
 
 
 
There were no significant differences among groups in values of the day 32 to 
day 2 ratio of R. equi-specific serum IgA (Fig. 7A); however, the ratios were 
significantly (P < 0.05) less than 1 for all groups.  The day 32 to day 2 ratios of serum 
IgG1 and IgG4/7 were significantly (P < 0.05) greater for the LVRE group than other 
groups (Fig. 7 B and C); there were no other significant differences among groups.  
Similarly, the ratios were significantly (P < 0.05) greater for the LVRE group than the 2 
A B 
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vaccine groups (but not controls; Fig. 7D).  Note that the magnitudes of increase were 
generally small.   
 
 
 
Fig. 7. Mean ratio of R. equi-specific IgA and IgG isotypes in serum samples from foals. OD on 
day 32 relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups as described in Fig. 2. 
Symbols with differing letters indicate significant (P < 0.05) differences among groups. A) R. equi-
specific IgA; B) R. equi-specific IgG1; C) R. equi-specific IgG4/7; D) R. equi-specific IgG3/5. 
 
 
 
 
 
 
 
 
 
 
 
A B 
D C 
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Mucosal humoral immune response 
Naso-pharyngeal samples 
Total IgA concentration in naso-pharyngeal samples were increased for all but 1 
foal; however, there were no significant differences among groups in either the relative 
magnitude of increase from day 2 to day 32 (Fig. 8A) or the proportion of foals that had 
increased IgA following vaccination (Fig. 8B), although the EBRE2 and LVRE groups 
tended to be increased. Although the relative increase of R. equi-specific IgA in NP 
samples tended to be greater for the EBRE2 and LVRE groups (Fig. 8B), there were no 
significant differences among groups. The proportions of foals that had increased  
R. equi-specific IgA, however, differed significantly among groups (P = 0.0223; Fisher’s 
exact test [FET]; Fig. 8D).  Post-hoc specific pair-wise comparisons indicated that the 
proportion of foals in the EBRE2 group that had increased R. equi-specific IgA was 
significantly (P < 0.05) greater than that of the saline controls (Fig. 8D).   
BAL fluid 
The ratio of total and R. equi-specific IgA and IgG isotypes for Day 32 relative to 
Day 2 were significantly (P < 0.05 for all) greater than 1 for all groups, indicating a 
significant increase with age (Fig. 9); however, there were no significant differences 
among groups in the values of these ratios. No significant association was observed in 
either total or R. equi-specific IgA between samples of BAL fluid and NP swabs from 
individual foals (Fig. 10). 
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Fig. 8. Mean ratios of total and R. equi-specific IgA in naso-pharyngeal samples. Relative quantities on 
day 32 relative to day 2 (log10-transformed) of IgA from 34 foals in 4 treatment groups as described in Fig. 
2. Symbols with differing letters indicate significant (P < 0.05) differences among groups.  A) Mean ratio 
(95% confidence interval) concentration total IgA; B) Mean ratio OD R. equi-specific IgA; C) Proportion 
of foals with increase in total IgA from day 32 relative to day 2; D) Proportion of foals with increase in R. 
equi-specific IgA from day 32 relative to day 2; overall distribution differed significantly among groups (P 
= 0.0223; FET); letters indicate results of post-hoc pair-wise testing between groups using FET. 
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Fig. 9. Mean ratio of total and R. equi-specific IgA and IgG isotypes on BAL fluid from foals. Relative 
quantities concentrations (total) and OD (R. equi-specific) on day 32 relative to day 2 (log10-transformed) 
from 34 foals in 4 treatment groups as described in Suppl. Fig. 4. Bars with differing letters indicate 
significant (P < 0.05) differences among groups. A) Total IgA; B) Total IgG1; C) Total IgG3/5; D) Total 
IgG4/7. E) R. equi-specific IgA; F) R. equi-specific IgG1; G) R. equi-specific IgG3/5; H) R. equi-specific 
IgG4/7.  
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Fig. 10. Association between mean ratio BAL fluid R. equi-specific IgA concentration from foal NP swab 
eluates and BAL fluid. Relative quantities on day 32 relative to day 2 (log10-transformed) from 34 foals in 
4 treatment groups as described in Suppl. Fig. 4. There was no significant association (P = 0.5907; 
Pearson’s correlation coefficient = 0.0956) between the BALF R. equi-specific IgA and the nasal R. equi-
specific IgA values for foals.  
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Maternal influence 
All mares had detectable total and R. equi-specific immunoglobulins of all 
classes in both milk and serum from natural exposure to R. equi in the environment. 
There was a significant correlation between milk and serum for total and R. equi-specific 
IgA, IgG1, IgG4/7, IgG3/5, except for total concentrations of IgG1 and IgG4/7; however, no 
differences among treatment groups of foals were observed (Appendix N).  
Because milk and serum concentrations were correlated for most isotypes and 
because colostrum/milk is the vehicle for antibody transfer to foals, we examined the 
correlation of immunoglobulins in milk with that of foal serum (Appendix O).  There 
was a significant (P < 0.05) positive association for IgA and a tendency (0.05 < P < 0.11) 
for a positive association for IgG4/7 and IgG3/5 between milk and foal serum on day 2; 
there was no apparent association for IgG1 (Fig. 11). No significant differences among 
groups were observed. There was a significant (P < 0.05) correlation between mare’s 
milk concentration and foals NP swab concentrations for both total and R. equi-specific 
IgA on day 2 of life (Appendix P); however, there was no significant difference among 
groups.  
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Fig. 11. Association between milk and foal serum samples on day 2 for R. equi-specific immunoglobulins. 
A) IgA; the association was weak but statistically significant; B) IgG1; the association was weak and not 
statistically significant (P = 0.1345); C) IgG4/7; the association was weak and not statistically significant (P 
< 0.0001); D) IgG3/5; the association was weak but statistically significant (P < 0.0001). 
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Discussion 
 
The objectives of this study were to render R. equi non-replicating with e-beam 
irradiation and to examine the immunogenicity of the e-beamed R. equi administered 
enterally to foals. Viability of R. equi was inversely related to e-beam irradiation dose 
(Fig. 1), as previously reported for other microorganisms including Escherichia coli K-
12 [124], Bacillus atrophaeus [125], and avian influenza virus [123]. As expected, a 
higher dose of irradiation was required to completely inhibit replication of a higher 
concentration of R. equi. Thus, the dose of irradiation for a vaccine preparation would 
need to be established for the concentration of bacteria produced. Depending on the 
bacterial growth phase, a higher dose might be needed for complete killing because 
bacterial cells in logarithmic growth phase can have multiple copies of their genomes per 
cell [172].  
At the doses selected, outer cell wall integrity appeared to be conserved.  We 
observed similar ratios for both concentrations of irradiated bacteria tested and live 
samples for all time-points (day 1, weeks 1, 2, and 4), whereas the heat-inactivated 
samples were considered damaged at all time-points. This finding was anticipated 
because e-beam irradiation was expected to damage the bacterial DNA [172], but 
damage to the cell wall might be dose-dependent and consequently titratable.  For 
example, e-beam irradiation of spores of Bacillus spp. caused membrane disruption with 
cytoplasm leakage when high doses (i.e., ≥10.4 kGy) were used but not at lower doses 
[131]. We did not evaluate bacterial structure in samples irradiated with > 5 kGy in our 
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study, however. Using TEM, all control and irradiated samples preserved the overall 
structural integrity of the cell wall [173], meaning that changes in the cell wall indicative 
of destruction or perforation of the bacterial cell wall were not observed. However, 
morphologic changes affecting ultrastructural components of the cell wall (e.g., the 
layered cell wall) and internal structures (e.g., nuclear area and glycogen-like deposits) 
were observed.    Although variation in severity of changes involving the ultrastructural 
components of the cell wall was found between the irradiated and heat-inactivated 
groups, morphologic changes in internal structures only were detected in the heat-
inactivated bacteria. Preservation of the cell wall integrity after e-beam irradiation has 
also been shown for Paracoccidioides brasiliensis [130], and membrane damage of 
Bacillus spp. spores was observed only at high doses of e-beam irradiation [131]. 
Although the evaluation of the ultrastructure in our study did not reveal changes in the 
cell wall indicative of perforation or destruction of the cell in any of the treatment 
groups, data from the fluorescence assay, coupled with the presence of more severe 
ultrastructural changes affecting the layered cell wall of heat-inactivated bacteria, 
indicate that the cell wall of heat-inactivated bacteria were more severely compromised 
relative to the other treatment groups.  For this study, we used a heat-inactivation 
protocol of 85oC for 30 min.  Other heat-killing protocols using more prolonged 
exposure, higher temperatures, or both likely would have caused more pronounced 
changes in the R. equi ultrastructure.   Nevertheless, we observed that e-beam 
inactivation resulted in better maintenance of normal membrane integrity and structure.   
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We observed that these structurally intact but non-replicating bacteria were 
immunogenic in neonatal foals.  We chose to evaluate immune responses during the first 
month of life on the basis of evidence that natural infection with R. equi generally occurs 
early in life [31, 32].  We elected to use ratios (day 32 values relative to day 2) because 
of considerable variation in absolute values among individual foals and between ages 
(e.g., declining total antibody concentrations or increasing IFN-γ production with age). 
Cell-mediated immune responses are of irrefutable importance to immunity to 
intracellular pathogens, including R. equi [47]. Neonatal foals, however, are known to 
have age-related impaired ability to produce IFN-γ, [81] [82], which is essential for 
activating macrophages to kill intracellular R. equi [103].  Consistent with previous 
findings, we observed that IFN-γ expression by PBMCs increased with age (both basal 
and stimulated expression).  More importantly, neonatal foals vaccinated with either 
dose of e-beam irradiated R. equi produced significantly greater IFN-γ in response to 
stimulation with R. equi than did controls, and this indicator of CMI was similar to that 
generated by the LVRE group (the positive control). These results indicate that enteral 
mucosal vaccination with irradiated bacteria can stimulate systemic CMI responses in 
neonatal foals despite consumption of colostrum with presumably specific antibodies 
against R. equi (based on the presence of R. equi specific in milk on day 2 postpartum) 
and natural exposure to environmental R. equi similar to those induced by enterally-
administered live R. equi. Unpublished data from our laboratory showed that R. equi has 
been isolated from air from the stalls and pastures where the foals were kept in this 
study, as well as from mare feces. Therefore, we believe all foals are naturally exposed 
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to R. equi, justifying the detection of specific immune responses from control foals. 
Also, evidence exists that foals are infected in the first 2 weeks of life [31, 32]. Thus, 
even immunologically naïve newborn foals can be primed to fight intracellular 
pathogens such as R. equi at the very susceptible early age. The results from the LVRE 
group are of further importance because they extend our knowledge of CMI responses to 
enteral administration of live, virulent R. equi, the only approach repeatedly 
demonstrated to protect foals against subsequent experimental intrabronchial challenge 
with virulent R. equi [35, 36].  
The concentration of total immunoglobulins of all isotypes in foal serum 
decreased with age but there was no significant difference among treatment groups. Age-
related decline in maternal antibody has been demonstrated in foals [79, 174], and was 
expected as a result of consumption and catabolization of maternally-derived 
immunoglobulin [174]. Foals from the LVRE group had significantly higher ratios of 
serum R. equi-specific IgG1 and IgG4/7 compared to other groups, and in IgG3/5 
compared to both groups of vaccinates (but not saline control foals).   The importance of 
these findings remains to be determined.  Reported associations of specific IgG isotypes 
with protection against R. equi are inconclusive and conflicting. Initially, it was 
suggested that IgG1 was expected to be protective because it represented a Th1 isotype, 
whereas and IgG3/5 and IgG4/7 were Th2 isotypes [89], while both IgG1 and IgG4/7 
interact with Fc receptors on effector cells and activate complement [88]. Subsequent 
studies, however, have indicated that IgG isotype dominance is not indicative of 
protection against R. equi in foals [35].  The magnitude of observed increase was modest 
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for IgG3/5 and IgG4/7, with neither ratio (day 32 to day 2) being significantly greater than 
1.  Nonetheless, enteral administration of e-beam inactivated bacteria did not result in 
similar serum antibody responses as enteral administration of live R. equi.  The 
relevance of this result to protection against infection is an important consideration that 
remains to be determined.  
Nasal mucosal R. equi-specific IgA appeared to be increased among foals in the 
higher-dose vaccine group (EBRE 2) than saline controls; the increase for the EBRE 2 
foals was similar to the LVRE group (positive controls) in magnitude of the ratio and 
proportion of foals whose ratio increased between days 2 and 32.  IgA is an important 
immunoglobulin at mucosal surfaces that functions primarily as a neutralizing antibody, 
but can also opsonize and activate complement [95]. Infection with R. equi in foals is 
thought to occur by inhalation of the bacterium [47], so IgA in nasal secretions may be 
an important barrier to R. equi infections in nasal passages by either neutralizing inhaled 
bacteria or by opsonizing them for subsequent phagocytosis and killing by macrophages 
in the lungs.  Although CTB is an adjuvant known to induce IgA responses at mucosal 
surfaces [137], we nonetheless observed a significantly higher proportion of foals from 
the EBRE2 group with increased R. equi-specific nasal IgA compared to the saline 
control group.  We observed that both total and R. equi-specific nasal IgA amounts 
increased significantly with age, consistent with what has been reported previously for 
total IgA [48]; to our knowledge, this is the first such report for R. equi-specific nasal 
IgA.  These findings indicate nasal mucosal immunity may be relatively diminished in 
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newborn foals, possibly rendering them more susceptible to respiratory mucosal 
infection. 
Because R. equi primarily causes pneumonia in foals, we evaluated 
immunoglobulin concentrations in BAL fluid of study foals. Similar to IgA from NP 
samples, we observed age-related increases (i.e., day 32 to day 2 ratios significantly 
greater than 1) in BAL fluid total and R. equi-specific IgA, IgG1, IgG3/5, and IgG4/7; 
however, no significant differences were observed among groups for any isotype. As 
was observed in the foals of this study, IgG and not IgA  is the most abundant antibody 
in human BAL fluid [175]. The concentrations of R. equi-specific immunoglobulins of 
all isotypes in BAL fluid were very low, and in some instances undetectable, especially 
on day 2.  We thus repeated analyses after concentrating the BAL fluid but results were 
essentially identical to those presented for the original analysis.  It is unclear to what 
extent our BAL technique affected our results.  We chose to use a low-volume BAL (30 
ml) on the basis of previous research in sheep, in an attempt to yield more concentrated 
BAL [176-178]. Typically larger volumes such as 180 ml [179] and 500 ml [26]  are 
used to obtain BAL samples from foals. Conceivably, a larger lavage volume might have 
provided greater contact with lung tissue, yielding a larger volume of fluid with more 
immunoglobulins.  
Both total and R. equi-specific antibodies of all isotypes were identified in both 
milk and serum from mares, and these antibodies were likely passively transferred to the 
foal via colostrum and milk. Transfer of antibodies to the foals from colostrum usually 
occurs in the first 24 h after birth [180]. We acknowledge that milk on day 2 postpartum 
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will unlikely have the same levels of immunoglobulins as those found in colostrum. 
There were, nonetheless, positive associations between all immunoglobulin isotypes in 
the dams’ milk and foals serum and NP swab samples from day 2. One frequent concern 
regarding vaccination of newborns is the presence and interference of maternal 
antibodies that could neutralize the vaccine, impairing the newborn’s response to the 
vaccine. We did not observe this in the present study; in fact, we observed the generation 
of a CMI response in spite of the presumed presence of maternal antibodies. This 
situation has also been demonstrated with vaccination against measles in 6-month-old 
infants [181], where there was significant generation of IFN-γ producing CD4+ T cells in 
spite of the presence of maternal antibodies, demonstrating that mucosal vaccination in 
neonates can be efficacious in priming the immune system.  
Our study has a number of limitations. First, enteral administration of 4 doses of 
vaccine is impractical for large-scale use at farms. It may nevertheless represent a 
strategy that is less cumbersome, labor-intensive and risky for the foals than the accepted 
and widespread use of prophylactic IV plasma. However, that does not preclude us from 
pursuing a new formulation for use as an oral paste less frequently in the future. Second, 
we determined the IFN-γ concentration using supernatant of cultured PBMCs stimulated 
in vitro with either ConA or e-beam inactivated R. equi. We are aware that different 
populations of cells could be producing IFN-γ, nevertheless, we were able to 
demonstrate that vaccinated foals responded better than control to e-beam inactivated  
R. equi, irrespective of the cell source, and in a similar way to foals receiving LVRE, 
known for inducing protective immune responses against R. equi challenge. Third, we 
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recognize that no vaccine is proven efficacious until protecting foals from challenge with 
the bacterium, and challenge studies are currently being performed. 
In summary, we demonstrated that e-beam can safely inactivate R. equi for 
potential use in vaccines, without compromising cell wall integrity. We also showed that 
R. equi inactivated with e-beam doses of either 4 or 5 kGy can be immunogenic in foals 
when administered enterally with CTB as adjuvant.  
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EFFECTS OF ADMINISTRATION OF LIVE OR INACTIVATED VIRULENT 
RHODOCOCCUS EQUI AND AGE ON THE FECAL MICROBIOME OF 
NEONATAL FOALS* 
 
Introduction 
 
Rhodococcus equi is a facultative intracellular pathogen that primarily infects 
macrophages [6]. Although human beings may be infected (primarily those who are 
immunocompromised by HIV infection or immunosuppressive treatments), R. equi is 
most commonly recognized clinically as a leading cause of severe pneumonia in foals 
[5-8]. The disease occurs among foals worldwide [5-8]. Isolates that are virulent in foals 
bear a plasmid that encodes for a pathogenicity island, which includes the gene for the 
virulence-associated protein A (vapA); vapA is necessary but not sufficient to cause 
disease [33, 51].   
Despite the global importance of the disease, an effective vaccine is lacking for 
control and prevention of R. equi pneumonia in foals. The lack of an effective vaccine is 
likely attributable to the complexity of immunity to R. equi [28-30], and the finding that 
foals appear to be infected very early in life [31, 32], when immune responses are naïve 
  
*Reprinted with permission from “Effects of Administration of Live or Inactivated 
Virulent Rhodococccus equi and Age on the Fecal Microbiome of Neonatal Foals” by 
Bordin AI, Suchodolski JS, Markel ME, et al. PLoS ONE 2013; 8(6):e66640, Copyright 
[2013] by Public Library of Science (PLOS).  
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or deficient.  It is generally accepted that a vaccine must be able to provide foals with 
protection against infection with R. equi during early life [33].  
To date, the only vaccination strategy that has been demonstrated repeatedly to 
be effective for protecting against experimental intrabronchial challenge with virulent  
R. equi has been oral administration of live, virulent R. equi [35, 36, 157]. Protection 
against respiratory pathogens induced by oral vaccination also has been documented in 
mice [114-116], and evidence exists that bacillus Calmette-Guerin (BCG) administered 
orally is protective against tuberculosis in people and animals [182-184].  Moreover, 
inactivated bacteria and viruses also can elicit protective immune responses against 
systemic infections, including those of the respiratory tract [158-161].  Despite the 
success of oral administration of live organisms to protect foals against experimental 
challenge, very limited information is available regarding immune and other biological 
responses to the enteral route of vaccination. 
One issue of importance with regard to enteral vaccination with live organisms is 
the impact of enteral administration of bacteria on the intestinal microbiome.  This 
question might be particularly important for neonates.  Although the microbiome of foals 
has not been systematically evaluated, evidence exists in other species, including 
humans, that the intestinal microbiome of neonates develops with age [148-150], and is 
linked to the functional development of the gut and gut immunity [148-150, 152, 153]. 
Thus, the purpose of the study reported here was to determine whether age-related 
changes in the microbiome occur in foals and whether age-associated changes are 
impacted by administration of either live virulent R. equi at a dose documented to protect 
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foals against experimental challenge or 2 doses of inactivated virulent R. equi higher 
than the dose of live R. equi.      
 
Materials and methods 
 
Ethics statement 
All procedures for this study, including collection of rectal swab samples and 
enteral treatments/vaccinations, were reviewed and approved by the Texas A&M 
University Institutional Animal Care and Use Committee (protocol number AUP # 2011-
124) and the Texas A&M University Institutional Biosafety Committee (permit number 
20110183-Cohen).  The foals used in this study are owned by Texas A&M University, 
and permission for their use was provided in compliance with the Institutional Animal 
Care and Use Committee procedures. 
 
Animals and housing 
Forty-two healthy Quarter Horse foals were used for this study. All foals were 
born healthy and had age-appropriate results of complete blood count (CBC) on day 2 of 
life, and adequate transfer of passive immunity as assessed by a commercially-available 
qualitative immunoassay for serum concentration of total IgG (SNAP Foal IgG test; 
IDEXX, Inc., Westbrook, ME). The foals were assigned into 1 of 5 experimental groups 
prior to birth (please see section on Vaccine Preparation and Treatment Groups below).  
All foals were monitored daily by Texas A&M University Horse Center staff for clinical 
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signs of disease, and inspected at least twice weekly by a veterinarian for clinical signs 
of disease.  All foals remained free of clinical signs of disease and in good health 
throughout the study. 
 
Mare diet 
The respective dams were fed 6.4 kg per horse per day of a 13% horse pellet 
(crude protein: 13.5%; crude fat: 4.5%; crude fiber: 10%).  Also, the foals and their 
mares were allowed free access to coastal Bermuda grass hay, plus grazing of pastures at 
the Texas A&M University Horse Center where the mares were maintained. 
 
Vaccine preparation and treatment groups 
Rhodococcus equi strain EIDL 5-331, obtained from a Texas foal confirmed to 
have R. equi pneumonia, was used to prepare live and inactivated vaccines used for this 
project. Physiological saline (NaCl 0.9%) was used as a diluent to achieve the specified 
concentration of all vaccine preparations, as well as for the negative control. The vaccine 
was produced by inoculating blood agar plates with 1 colony forming unit (CFU) of  
R. equi strain 5-331 and incubating at 37oC for 48 hours. One colony from this pure 
culture was selected and used to inoculate 1,000 ml of brain heart infusion (BHI, 
BactoTM Brain Heart Infusion, BD Diagnostic Systems, Sparks, MD) broth. The flask 
with inoculated broth was placed on an orbital shaker (VWR OS-500, VWR, Radnor, 
PA) at 200 rpm for 24h at 37oC to allow bacterial growth.  Isolates were repeatedly 
tested by PCR for the vapA gene to confirm that the isolates were virulent [185]. The 
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bacterial culture was inactivated by electron-beam irradiation (irradiation dose between 
4 and 5 kGy). After inactivation, the irradiated bacterial cells were plated out on BHI 
agar plates and incubated for 2 weeks at 37oC to confirm inactivation.  
The number of foals in each group was determined a priori, and foals were 
assigned randomly to each of the groups.  The study groups were as follows: 1) low-dose 
inactivated virulent R. equi group (n = 9), receiving 2 × 1010 CFUs of inactivated R. equi 
combined with 100 µg of cholera toxin subunit B (CTB, List Biological Laboratories, 
Campbell, CA) as a mucosal adjuvant, diluted in 100 ml of saline administered via 
nasogastric intubation; 2) high-dose inactivated virulent R. equi group (n=10), receiving 
1 × 1011 CFUs of inactivated R. equi with 100 µg of CTB diluted in 100 ml of saline via 
nasogastric intubation; 3) live virulent R. equi group (n=6), receiving  1 × 1010 CFUs of 
live R. equi diluted in 100 ml of saline administered via nasogastric intubation; 4) 
control with CTB group (n=9), receiving 100 µg of CTB diluted in 100 ml of saline via 
nasogastric intubation; and, 5) control without CTB group (n = 8), receiving 100 ml of 
saline via nasogastric intubation.  Treatments (i.e., live bacteria, inactivated bacteria, and 
negative controls) were administered by nasogastric intubation to foals at 2, 9, 16, and 
23 days of age.    
 
Fecal swabbing 
Rectal swabs were collected by inserting a 16-inch, cotton-tipped swab that was 
pre-moistened with 3 ml of sterile saline approximately 2 to 3 inches into the rectum, 
and swabbing the rectal mucosa circumferentially by rotating the swab. Once the cotton 
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swab was removed, the cotton tip was separated from the handle using scissors and the 
tip was placed inside the barrel of a 35-ml catheter-tip syringe; the syringe plunger was 
used to squeeze the liquid from the swab tip, and the liquid was collected into a sterile 
tube.  Fecal swab samples were collected on days 2 and 32 of life from foals in all 
groups. For 2 foals in the control group without CTB, fecal swab samples were collected 
on days 2, 9, 16, 23, 32, and 56 following birth. All fecal solutions were frozen at -80oC 
until processed. 
 
Fecal DNA extraction 
DNA was extracted by a bead-beating method using the ZR Fecal DNA 
MiniPrep Kit (Zymo Research Corporation) per the manufacturer’s instructions.  The 
bead-beating step was performed using a homogenizer (FastPrep-24, MP Biomedicals) 
for 60 s at speed of 4 m/s. 
 
Microbiome analysis  
Bacterial tag-encoded FLX-titanium amplicon pyrosequencing (bTEFAP) was 
performed as described previously [186]  based upon the V4-V6 region (E. coli position 
530 – 1100) of the 16S rRNA gene, with primers forward 530F: 
GTGCCAGCMGCNGCGG  and reverse 1100R: GGGTTNCGNTCGTTR.  
Raw sequence data were screened, trimmed, filtered, de-noised, and chimera-
depleted with default settings using the QIIME pipeline version 1.6.0 
(http://qiime.sourceforge.net) and with USEARCH using the OTU pipeline 
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(www.drive5.com). Operational taxonomic units (OTUs) were defined as sequences 
with at least 97% similarity using QIIME. For classification of sequences on a genus 
level the naïve Bayesian classifier within the Ribosomal Database Project (RDP, v10.28) 
was used [186]. 
The obtained data were compiled to determine the relative proportions of bacteria 
for each individual sample. The subsequent analysis was performed on a randomly 
selected subset of 1,300 sequences per sample to account for unequal sequencing depth 
across samples. Alpha diversity and beta diversity measures were calculated and plotted 
using QIIME. To determine differences in microbiota composition between the animal 
groups, the analysis of similarities (ANOSIM) function in the statistical software 
package PRIMER 6 (PRIMER-E Ltd., Lutton, UK) was used on the unweighted Unifrac 
distances matrices. This analysis measures the phylogenetic distance among bacterial 
communities in a phylogenetic tree, and thereby provides a measure of similarity among 
microbial communities present in different biological samples. The linear discriminant 
analysis (LDA) effect size (LEfSe) method was used to represent taxonomic relevant 
age-related differences in foal fecal swabs [187]. 
 
qPCR 
To validate the pyrosequencing results, quantitative PCR (qPCR) assays were 
performed as described previously [188]. Briefly, EvaGreen-based reaction mixtures 
(total 10 µL) contained 5 µL of SsoFastTM EvaGreen® supermix (Biorad Laboratories), 
2.2 µL of water, 0.4 µL of each primer (final concentration: 400 nM), and 2 µL of DNA 
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(normalized to 5ng/µl). PCR conditions were 98°C for 2 min, and 40 cycles at 98°C 5 s, 
and 5 s at the optimized annealing temperature (Table 1). A melt curve analysis was 
performed for under the following conditions: beginning at 65 °C, gradually increasing 
0.5 °C/ 5 s to 95 °C with acquisition data every 5 s. The qPCR data was expressed as log 
amount of DNA (fg) for each particular bacterial group per 10 ng of isolated total DNA 
[189].  
 
 
 
 
Table 1 
Oligonucleotide primers/probes used for this study 
 
qPCR primers/probe Sequence (5’- 3’) Target Annealing (°C) Reference 
CFB555f CCGGAWTYATTGGGTTTAAAGGG Bacteroidetes 60 [190] 
CFB968r GGTAAGGTTCCTCGCGTA    
Fuso-F KGGGCTCAACMCMGTATTGCGT Fusobacteria 51 [189] 
Fuso-R TCGCGTTAGCTTGGGCGCTG    
341-F CCTACGGGAGGCAGCAGT Universal Bacteria 59 [191] 
518-R ATTACCGCGGCTGCTGG    
EntF CCCTTATTGTTAGTTGCCATCATT Enterococcus 61 [192] 
EntR ACTCGTTGTACTTCCCATTGT    
EcolRT_F GTTAATACCTTTGCTCATTGA E. coli 55 [193] 
EcolRT R ACCAGGGTATCTAATCCTGTT    
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Data analysis 
Pairwise comparisons between ages 2 days and 32 days were made at the levels 
of phylum, class, order, and family of bacteria for 2 outcomes: the observed percentage 
of sequences of bacteria at a given level, and the proportion of foals in which any 
amount of a given sequence for a given level was observed (i.e., the dichotomous 
outcome of whether or not a specific phylum [or class or order or family] was 
represented).  The paired differences in percentages were compared using a Wilcoxon 
sign-rank test, and the paired proportions were compared using McNemar’s test. 
Because of the multiplicity of comparisons, P values at a given level (e.g., order) were 
adjusted using the method of Hochberg [194]. An adjusted P value < 0.05 was 
considered significant for these analyses.  Analyses were conducted using S-PLUS 
(Version 8.0; Insightful, Inc.) and R (Version 2.12.1; R Statistical Project).   To assess 
the diversity of the GI microbiota, the Shannon-Weaver [195] and Chao 1 [196] diversity 
indices were calculated in QIIME. 
 
Results 
 
Sequence analysis 
The 454-pyrosequencing pipeline yielded 499,419 quality sequences for the 42 
samples analyzed. For technical reasons attributed to random error, 5 foals (2 foals from 
the control group without CTB, and 3 foals from the live R. equi group) did not generate 
sufficient sequences (cut-off value of 1,300 sequences) in at least 1 sample from 1 
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sampling time-point (either 2 or 32 days) by 454-pyrosequencing. Those foals were 
included in the descriptive analysis (Fig. PCoA and rarefaction). For comparing age-
related changes of the microbiome, however, the analysis was restricted to 37 foals with 
samples available from both collection time-points (2 and 32 days).  
Across all vaccination groups and ages, sequences were classified into 18 phyla 
(Table Q-1 and R-1, please see appendices Q and R). For the rarefaction curves of all 
vaccination groups (Fig. 12A and 12B) and age groups (Fig. 13), 1,300 sequences per 
sample yielded stable estimates of sample diversity.  
 
 
 
Fig. 12. Rarefaction analysis of 16 S rRNA gene sequences obtained from fecal swabs from foals of 
different treatment vaccination groups. Lines represent the average of each vaccination group at all ages 
(panel A) or at 32 days only (panel B), while the error bars represent the standard deviations. The analysis 
was performed on a randomly selected subset of 1,300 sequences per sample and included samples from 
42 foals. Note that both the greatest and least number of species observed occurred among foals that 
received no enteral bacteria (live or inactivated), indicating an absence of evidence of treatment effect. 
Control  =  control plus CTB group; Control_no_CTO  =  control without CTB group; High  =  high-dose 
inactivated R. equi group; Live  =  live R. equi group; Low  =  low-dose inactivated R. equi group. 
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Fig. 13. Rarefaction analysis of 16 S rRNA gene sequences obtained from fecal swabs from foals at 
different ages. Lines represent the average numbers obtained at each age (legend numbers refer to the age 
in days), while the error bars represent the standard deviations. The analysis was performed on a randomly 
selected subset of 1,300 sequences per sample and included samples from 42 foals.  Note the progressive 
increase in observed species (representing microbial diversity) with sequential age.  The numbers for the 
legend represent age (in days). 
 
 
 
 
 
Microbial communities in control and vaccinated foals 
No differences in microbial composition were observed among animals from 
control, live and inactivated treatment/vaccination groups (Fig. 12A, 12B, and 14).  The 
rarefaction curves for the treatment groups revealed no clear pattern of greater number of 
observed species (i.e., diversity) among foals receiving either live or inactivated R. equi, 
or those foals in the 3 control groups that did not receive R. equi (Fig. 12A).  Because 
the samples at age 2 days were not affected by treatment (because treatment was 
administered after sample collection on day 2), we also performed analysis restricting 
data to samples collected at age 32 days (Fig. 12B). Once again, there was no pattern of 
differences in the rarefaction curves among treatment groups receiving either live or 
inactivated R. equi or the control groups. Using PCoA (Fig. 14 and 15), there was no 
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qualitative evidence of differences among groups; the clustering observed in Fig. 7 panel 
A was attributable to effects of age (please see next section).  When considering only the 
data from foals at 32 days of age (because samples on day 2 were collected prior to 
treatment administration), the PCoA plots revealed no clustering by group and the 
ANOSIM test statistic for differences among groups was not significant (P = 0.494).    
 
 
 
 
Fig. 14. Principal coordinates analysis (PCoA) of unweighted UniFrac distances of 16 S rRNA genes for 
foals of different treatment vaccination groups at all ages. Analysis for 42 foals in groups control with 
CTB (red square), control without CTB (yellow triangle), low-dose inactivated R. equi (dark blue 
triangle), high-dose inactivated R. equi 2 (green dot), and live R. equi (light blue triangle) at 2 and 32 days 
of age (ANOSIM, P = 0.236).  The 3 panels represent the comparison of the first 2 principal components 
(A), the second and third principal components (B), and the first and third principal components (C). The 
pattern in the panel A is attributable to effects of age (please see Fig. 15 and 16). 
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Fig. 15. Principal coordinates analysis (PCoA) of unweighted UniFrac distances of 16 S rRNA genes for 
foals of different treatment vaccination groups at 32 days of age. Analysis for 42 foals in groups control 
with CTB (red square), control without CTB (yellow triangle), low-dose inactivated R. equi (dark blue 
triangle), high-dose inactivated R. equi 2 (green dot), and live R. equi (light blue triangle) at 32 days of age 
only. Differences among groups were not significant (ANOSIM, P = 0.449). The 3 panels represent the 
comparison of the first 2 principal components (A), the second and third principal components (B), and the 
first and third principal components (C). 
 
 
 
 
 
Age-related changes in microbial communities in foals 
There were strong and significant differences in the fecal microbiome of foals 
associated with age. The rarefaction curves demonstrated a pattern of increasing number 
of species (diversity) with increasing age (Fig. 13). These results should be interpreted 
with caution because there were only 2 foals for which data for ages other than 2 days 
and 32 days were available.  The PCoA plots by age revealed an obvious separation of 
samples by age, attributable to differences between the time-points of days 2 and 32 
(Fig. 16); the ANOSIM test statistic for differences between day 2 and day 32 was 
significant (P = 0.0010).  
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Fig. 16. Principal coordinates analysis (PCoA) of unweighted UniFrac distances of 16 S rRNA genes for 
foals at different ages. Analysis for 42 foals at 2 (red triangle), 7 days old (yellow triangle), 14 (green dot), 
21 (green triangle), 32 (light blue square), and 56 days of age (dark blue triangle). The 3 panels represent 
the comparison of the first 2 principal components (A), the second and third principal components (B), and 
the first and third principal components (C). Strong effects of age can be seen in panels A and C, and 
differences among age groups were significant (ANOSIM, P =0.0010). 
 
 
 
 
 
Significant differences in the number of OTUs, the Shannon index, and the 
Chao1 metric were observed between the age groups (Table 2). The median number of 
OTUs for 2day-old foals (92 OTUs; range, 50 to 195 OTUs) was significantly (P < 
0.0001) lower than that for 32-day-old foals (201 OTUs; range, 94 to 318 OTUs).  The 
Shannon Index for the foals studied also increased significantly (P < 0.0001) from 2 days 
of life (median, 2.37; range, 1.24 to 3.97) to 32 days of life (median, 3.7; range, 1.90 to 
4.80). Similarly, there was a significant (P < 0.0001) age-related increase in Chao 1 
values between 2-day-old foals (median, 206.54; range, 128.16 to 415.70) and 32-day-
old foals (median, 362.38; range, 197.42 to 581.43).  
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Table 2  
Summary of alpha diversity measures  
 
Index 2 day-old 32 day-old P 
Chao 1 (median, range) 206.54 (128.16 to 415.70) 362.38 (197.42 to 581.43) <0.0001 
OTUs (median, range) 92 (50 to 195) 201 (94 to 318) <0.0001 
Shannon H (median, range) 2.37 (1.24 to 3.97) 3.7 (1.90 to 4.80) <0.0001 
 
 
 
 
Because of the apparent differences of the microbiota between age groups, we 
also compared the distribution of bacteria by phylum, class, order, and family between 
foals aged 2 days and 32 days.  In total, 18 phyla were detected in fecal samples from 
foals (Table Q-1, Appendix Q). Of those, Bacteroidetes (40.6%, day 32), Firmicutes 
(40.4%, day 2), and Proteobacteria (36.6%, day 2) had the highest percentages of 
sequences reported. Proteobacteria and Firmicutes were detected in all samples from 2-
day-old foals, followed by Bacteroidetes (92%) and Actinobacteria (73%) (Table R-1, 
Appendix R). Among 32-day-old foals, Bacteroidetes and Firmicutes were detected in 
all fecal samples, followed by Actinobacteria (97%) and Proteobacteria (97%), 
Verrucomicrobia (89%), and Fusobacteria (84%) (Table R-1, please see Appendix R). 
The following phyla increased significantly with age (i.e., from 2 days to 32 days of 
age): Euryarchaeota, Actinobacteria, Bacteroidetes, Chlamydiae, Chloroflexi, 
Planctomycetes, Spirochaetes, TM7, and Verrucomicrobia. Proteobacteria was the only 
phylum that decreased significantly with age. Other classes, orders, and families also 
showed statistically significant age-related changes (Table Q-1 and Fig. 17).  
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Within the phylum Proteobacteria, the class Gammaproteobacteria (P < 0.0001) 
and the family Enterobacteriaceae (P < 0.0001) decreased significantly with age. Other 
classes of Proteobacteria, such as Deltaproteobacteria (P = 0.0084) and 
Epsilonproteobacteria (P < 0.0001) significantly increased with age (Table Q-1). 
To confirm results of pyrosequencing, we also performed real-time quantitative 
PCR.  Significant differences were observed in specific microbial communities between 
the 2 age groups based on qPCR analysis, with age-related decreases for Escherichia 
coli (P < 0.0001) and for Enterococcus (P < 0.0001).  These data were consistent with 
genus-level results observed by pyrosequencing for Enterococcus (P = 0.0009) and for 
Escherichia (P < 0.0001). We also found agreement for a lack of evidence of a 
significant difference between the pyrosequencing and the qPCR results for 
Bacteroidetes (P = 0.9519 by qPCR and P = 0.5376 by pyrosequencing) and Fusobacteria 
(P = 0.1051 on qPCR and P = 0.1000 on pyrosequencing).  
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Fig. 17. LEfSe results on foal microbiome. Rotary phylogenetic representation of the predominate 
microbial composition of fecal samples from foals at 2 days of age (A, red) and 32 days of age (C, green) 
[187]. 
 
 
 
 
Discussion 
 
In this study, our first objective was to evaluate changes in the microbiome of 
foals following vaccination with both live and inactivated R. equi.  Although the number 
of CFUs administered were as high (for the live R. equi group) or higher than the 
number of CFU documented to protect foals against intrabronchial challenge with 
virulent R. equi (viz., 1 x 1010 CFU), no apparent differences in microbial communities 
  
 
67 
were observed among vaccinated groups (Fig. 12A and 14).  Because all but 2 foals had 
samples collected only on days 2 and 32, and because fecal samples on day 2 were not 
influenced by treatment (because they were collected immediately prior to treatment), 
the effect of group was also examined among only samples collected at 32 days of age.  
Results restricted to 32 days of age also revealed no pattern distinguishing vaccinated 
and non-vaccinated foals (Fig. 12B and 15). Thus, we failed to detect evidence of a 
significant effect of enteral administration of either live or inactivated R. equi on 
microbial populations in neonatal foals.  These results are consistent with reports in 
which probiotics (administered at similar or higher numbers of CFUs) have failed to 
alter the intestinal/fecal microbiome [197-199].  Our results should be interpreted with 
caution because of the relatively small number of foals, particularly in the live R. equi 
group.  For technical reasons attributed to random error, pyrosequencing failed for 
samples from 3 foals from the live R. equi group and 2 foals from the control group 
without CTB group; therefore, only 3 foals from the live R. equi group and 6 from the 
controls without CTB group were included in the analysis.   
A significant difference between the fecal microbial populations between day 2 
and day 32 of age was observed (Table Q-1 and R-1; Fig. 13, 16, and 17). For 
descriptive purposes, we included the results from the 2 foals from which we had data at 
other ages (these data were not included in the statistical analysis comparing ages).  The 
resident intestinal or fecal microbiota has been described for neonates of other species, 
such as cats [145, 146], dogs [147], and humans [148-151]. To the authors’ knowledge, 
this is the first report of age-related changes of the fecal microbiome in foals. Significant 
  
 
68 
changes in the number of OTUs, the Shannon index, and the Chao1 metric were 
observed between the age groups (Table 2), showing clear evidence of strong 
diversification of bacterial populations between 2 and 32 days of age.  
Firmicutes were detected in 100% of foals at both 2 and 32 days of age, with 
reported median sequences of 40% in 2-day-old foals decreasing (albeit not 
significantly) to 23% in 32-day-old foals. In 2 previous studies using fecal samples from 
adult horses, Firmicutes represented 44% [200] and 72% [201] of the bacteria. Within 
the Firmicutes, the family Enterococcaceae significantly decreased with age (P =	 
0.0080), which was likely attributable at least in part to decreases in the genus 
Enterococcus that were observed to decrease significantly by qPCR (P < 0.0001) and by 
pyrosequencing. Proteobacteria were detected in the feces of all 2-day-old foals and 97% 
of 32-day-old foals, a difference that was not significant; however, the median 
percentage of sequences decreased significantly (P < 0.0001) between day 2 (median, 
36.3%; range, 0.5 to 85.8%) and day 32 (median, 2.7%; range, 0 to 40.9%).  In adult 
horses, Proteobacteria have been reported to represent 6% [200] and 12% [202] of fecal 
sequences. These results from adult horses are interesting in light of our findings, 
particularly our observation that the family Enterobacteriaceae decreased with age, a 
finding substantiated by our qPCR results with a significant decrease in the amount of E. 
coli (P < 0.0001) between ages 2 and 32 days.  
The sterile GI tract of newborn puppies and kittens is presumably colonized by 
bacteria present in the birth canal and from the environment [155], and human neonates 
appear to become colonized by these sources as well as through the intestinal microbiota 
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of the mother [148, 154]. In humans, the initial microbes colonizing infants are 
facultative anaerobic bacteria, such as E. coli and Streptococcus spp. [154], which was 
also observed in 2-day old foals by the presence of Enterobacteriaceae (E. coli) and 
Streptococcaceae families (Streptococcus spp.). We observed a significant decrease in 
both these families by 32 days of age, suggesting that a similar phenomenon might 
happen in foals. In human beings, after the initial colonization by facultative anaerobic 
bacteria, colonization occurs by Staphylococcus-, Enterococcus-, and Lactobacillus-like 
species, and this change might contribute to generating an anaerobic environment [151]. 
The development during the first month of life in foals of an anaerobic environment is 
supported by the age-related increase in the detection of the phylum of Bacteroidetes (P 
= 0.0066), which is also a common constituent of the gut microbiota of dogs and cats 
[155]. However, we also observed a significant decrease in the Enterococcaceae family 
(P =	 0.0080) and Enterococcus spp. by qPCR (P < 0.0001), as well as the 
Lactobacillaceae family (P = 0.0281).  
Our study has a number of important limitations.  One limitation is the use of 
fecal swab samples for analysis, because feces might not be representative of other 
compartments of the gut. In humans, the composition of the mucosal-surface microbiota 
is distinct from that recovered in the feces [175]. The situation is probably similar in the 
horse, because of the complexity of the equine gastrointestinal tract. For example, the 
microbial population of adult horse fecal samples is likely to represent that of the right 
dorsal colon, but not that of the cecum [156]. 
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A second limitation of our study is the small number of foals enrolled.  Our 
sample size was limited both by financial considerations and the number of foals 
available to us during the study period.  Because of the small sample size, we were only 
able to observe large changes in fecal microbial populations.  Nevertheless, our results 
provide useful data for those exploring enteral vaccination of foals [157, 203]. It is worth 
noting that there were significant differences in immune responses that were detectable 
among these groups of foals despite the small sample size (please refer to chapter II).  
Also, we were able to detect significant age-related differences in the microbiome of 
foals, irrespective of the treatment groups. 
Another limitation of our study is that we only characterized age-related changes 
at 2 ages during the first month of life.  Although our data from 2 foals with more 
frequent sampling appears to demonstrate a progressive diversification of microbial flora 
with age (Fig. 16), further studies using more foals with more frequent sampling times 
are needed to better characterize microbial diversification.  Our focus on the first month 
of life was based on current understanding that vaccination of foals against R. equi will 
have to occur during early life [204]. 
In conclusion, no differences were observed in the fecal microbiome of foals 
following enteral vaccination with either live or inactivated R. equi. These results 
demonstrate that administration of the doses of bacteria used in this study does not likely 
cause an alteration of the fecal microbiome of foals. More notably, the results indicate 
significant age-related changes in the microbiome composition of foals during the first 
month of life.    
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SUMMARY AND CONCLUSIONS 
 
Summary 
 
Rhodococcus equi pneumonia is an important cause of pneumonia in foals.  
Despite considerable effort, to date there is no vaccine that will protect foals against 
intrabronchial challenge with R. equi. The only approach that has been demonstrated 
repeatedly to protect foals from challenge is the administration of live, virulent R. equi. 
This strategy, however, is not acceptable for use in farms because of its potential to 
cause disease in the host, as well as concerns with environmental contamination and 
manufacturing of live vaccines. This dissertation describes development and initial 
assessment of the immunogenicity of e-beam irradiated bacteria as a candidate for an 
effective vaccine against R. equi pneumonia in foals. 
Two concentrations of R. equi were used to evaluate e-beam irradiation as a 
method of inactivation: 1 × 108 colony-forming units/ml (CFU/ml) and 1 × 109 CFU/ml. 
Both concentrations were submitted to a range of e-beam radiation doses, ranging from  
0 to 7 kGy. All microorganisms of both the lower and higher concentrations were 
completely inactivated by 4 and 5 kGy, respectively.  Moreover, the cell walls of the 
irradiated bacteria remained structurally intact, whereas heat-inactivated samples 
developed compromised cell walls. It was demonstrated that e-beam irradiation 
completely inactivated R. equi samples, while retaining their structural integrity.  
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The immunogenicity of 2 doses of vaccine were examined: the doses selected 
were 2- and 5-fold greater than the number of  bacteria (1 x 1010 CFU)  previously 
reported to protect foals against intra-bronchial challenge with live, virulent R. equi.  
Mucosal (NP swab eluates and BAL fluid) and serum antibody responses were studied, 
as well as cell-mediated immune responses (IFN-γ production by PBMCs in culture).  
The e-beam vaccine appeared to stimulate a robust cell-mediated immune response and, 
at the higher dose, upper respiratory tract mucosal IgA, in the face of maternally-
transferred antibody to foals.  These results encourage us to evaluate the effectiveness of 
this candidate vaccine for efficacy in protecting foals against R. equi pneumonia.   
The e-beam inactivated R. equi vaccine appeared safe, as no adverse effects were 
noted in study foals; however, vaccine safety will require hundreds of animals to identify 
common side-effects and thousands of animals to identify less common adverse effects.  
One aspect of safety consideration for enteral vaccines is the impact on the intestinal 
microbiome.  Although there were profound changes in the composition and diversity of 
the neonatal microbiome during the first month of life, enteral administration of either 
live R. equi or e-beam irradiated R. equi did not appear to alter the fecal microbiome.  
These results help us feel confident that neonatal enteral vaccination is not likely to 
impair the natural age-related expansion of composition and diversity of the intestinal 
microbiome.   
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Conclusions 
 
In summary, our conclusions were:  
1. Rhodococcus equi can be inactivated by e-beam irradiation without losing membrane 
integrity; 
2. enteral administration of live virulent R. equi induces detectable total and  
anti-R. equi IgA in nasal swab eluates and IgA and IgG1, IgG4/7, IgG3/5  isotypes in 
serum, as well as IFN-γ in supernatant of cultured PBMCs; it does not induce  
anti-R. equi-specific antibodies in BAL fluid; 
3. intragastric administration of either dose of enteral e-beam inactivated virulent  
R. equi to foals induced significant increases in the production of soluble IFN-γ in 
supernatant of cultured PBMCs, but does not induce significant changes in the 
amount of total and anti-R. equi IgA and IgG1, IgG4/7, IgG3/5  isotypes antibodies in 
BAL fluid and serum samples; 
4. the proportion of foals with increased R. equi-specific IgA is higher in foals 
receiving the higher dose of enteral e-beam inactivated virulent R. equi compared to 
those receiving saline (plus adjuvant);  
5. the 2 doses of enteral e-beam inactivated virulent R. equi induced similar serum and 
mucosal humoral responses, except the higher dose appears to induce stronger nasal 
R. equi-specific IgA;  
6. intragastric administration of either dose of enteral e-beam inactivated virulent  
R. equi or live R. equi to foals does not substantively alter the microbiome of foals; 
  
 
74 
however, significant age-related changes in the fecal microbiome composition and 
diversity were detected during the first month of life in foals; and,  
7.  enteral administration of e-beam irradiated R. equi merits evaluation for efficacy to 
protect against R. equi challenge infection in foals.   
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APPENDIX A 
 
Protocol for growing Rhodococcus equi strain 5-331 and vaccine preparation 
 
1. Inoculate blood agar plates with 1 colony-forming unit (CFU) of R. equi strain 5-331 
from an existing plate or from frozen beads kept at -80oC. 
2. Incubate at 37oC for 48 hours. 
3. Pick one colony from this pure culture and inoculate 1,000 ml of brain heart infusion 
(BHI, BactoTM Brain Heart Infusion, BD Diagnostic Systems, Sparks, MD) broth. 
4. Put the flask with inoculated broth on an orbital shaker (VWR OS-500, VWR, 
Radnor, PA) at 200 rpm for 24h at 37oC to allow bacterial growth. 
5. Transfer bacteria to 200 ml tubes and centrifuge at 3840 × g for 20 min. 
6. Discard supernatant, resuspend pellet in 100 ml of PBS. 
7. Centrifuge at 3840 × g for 20 min. 
8. Resuspend pellets in 20 ml of PBS. 
9. Combine all pellets in one tube and measure OD using a spectrophotometer. 
10. Dilute until either OD 1.0 or 2.0 is reached (depending on desired concentration). 
11. Once desired OD is reached, make serial dilutions and plate out in BHI agar plates to 
confirm bacteria concentration. 
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APPENDIX B 
 
Standard-operating procedure (SOP) for inactivation of biohazards using high energy 
electron-beam 
 
1. Purpose: 
1.1 The purpose of this SOP is to outline the steps involved in the inactivation of 
biohazardous materials using high-energy electron beam. 
2. Scope: 
2.1. This SOP applies to inactivation of biohazardous materials using high energy 
electron beam in the National Center for Electron Beam Research at Texas 
A&M University. 
3. Responsibilities 
3.1. The E-Beam Center guarantees only the delivery of defined doses of E-Beam 
and X-ray. The E-Beam Center does not guarantee the inactivation of target 
organisms. 
3.2. It is the responsibility of the investigator to inform the E-Beam Center the 
biological agent in question and the irradiation doses that are needed. 
3.3. The E-Beam Center will ensure that appropriate doses of E-Beam and X-ray are 
delivered.  
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3.4. The Office of Biosafety will approve this SOP. 
3.5. The Director of the National Center for Electron Beam Research will ensure that 
all personnel performing the procedures will be trained on the contents of this 
SOP. 
3.6. The Director of the National Center for Electron Beam Research will ensure that 
all work with biohazardous materials has been reviewed and approved by the 
Office of Biosafety /IBC. This will be confirmed by the E-beam Center Director 
or his designate by calling the Office of Biosafety and confirming that each PI 
requesting E-beam services has IBC approval for this aspect of the research 
project and for use of the E-beam Center. 
3.6.1. All Investigators will provide the E-beam Center Director a copy of their 
IBC approval letter to ensure that all necessary Office of Biosafety / IBC 
approvals have been obtained prior to working with biohazardous 
materials. 
3.7. All investigators will ensure that materials to be transported to the facility for 
inactivation are packed in accordance with applicable Office of Biosafety / IBC, 
local, state, and federal regulations. 
3.8. All personnel involved in the procedures are required to read and follow this 
SOP. 
4. Reference Documents and Forms: 
4.1. SOP# 001 Emergency Plan for Biohazard Leaking or Spill. 
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5. Training 
5.1. Personnel whose job involves inactivation of biohazards in the center must 
receive training on the contents of all Standard Operating Procedures. 
6. Equipment and Materials 
6.1. Cardboard “carrier” trays 
6.2. 10 MeV E-Beam and 5 MeV X-ray linear accelerators (LINACS) and control 
systems. 
6.3. Material handling conveyor belt system. 
7. General Instructions 
7.1. Biohazardous samples will be transported in Office of Biosafety / IBC approved 
durable, leak proof containers during handling, processing, storage, and 
transport to and within the facility. Depending on the experimental procedures, 
the infectious samples will be contained in heavy duty specimen transport bags. 
(An approved bag for this use: Infecon Heavy Duty Specimen Transport Bags, 
ML0419-20, 31, 32, 33, 34, and 35, Market Labs)  These transport bags will be 
placed within DOT approved transport boxes and transported to the E-beam 
center. 
7.2. Potentially infectious samples must be contained within the sealed, leakproof 
specimen bag throughout the irradiation process. 
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7.3. All external surfaces of the sample containers and sample bags must be 
disinfected prior to the transportation to the E-Beam Center.  
7.4. All containers containing biohazardous samples for processing must be 
delivered to the sample lab (room #102) located on the west end of the facility. 
7.5. All containers containing biohazardous samples must be properly labeled with: 
7.5.1. Name of PI, Phone number or contact information. 
7.5.2. Biohazard Symbol. 
7.5.3. Description of the biohazard/Contents of container (i.e. Agent name). 
7.5.4. Process degree desired if known. 
7.6. Upon arrival at the E-beam center, biohazardous samples contained in heavy 
duty, leakproof specimen bags will be removed from the DOT transport carrier 
and will be placed in a cardboard container, provided by the E-beam center, for 
processing and delivery of E-beam/X-ray dose and transport throughout the 
facility, preventing direct contact of the sample with the equipment. 
8. Procedure: 
8.1. Sample receiving process for containers of biohazardous samples to be 
irradiated: 
8.1.1. E-beam personnel will visually inspect the specimen bag containers 
containing biohazardous samples for integrity and evidence of any 
damage or leakage. 
  
 
109 
8.1.2. If there is any evidence that the biohazardous material may be leaking 
from the specimen bag container, follow the SOP 001 Emergency Plan 
for Biohazard Leaking or Spill. 
8.1.3. If no leakage is observed, log in sample in log book. 
8.2. Run speed check samples to ensure delivery of target dose. 
8.3. Perform dosimetry to verify delivered dose. 
8.4. Adjust belt speed as needed to control dose. 
8.5. Place samples, in cardboard carrier trays, on material handling conveyer belt 
system.  
8.6. Deliver target E-Beam/X-ray doses to the research samples. 
8.7. Remove samples from carrier trays and transfer the primary container back into 
the secondary (DOT) container for transport out of the facility. 
8.8. Call responsible PI to pick up irradiated samples. 
8.9. Irradiated samples are not to be stored within the facility. Irradiated samples are 
returned to the PI’s lab and autoclaved for 1 hour at 121oC prior to disposal. 
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APPENDIX C 
 
Vaccine preparation for electron-beam irradiation 
 
 
 
 
 
 
A) Vaccine in desired concentration was added to the first plastic container; 
B) Second plastic container with the first container after being heat-sealed and trimmed; 
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C) Second container was heat-sealed and trimmed to fit the transport bag; 
D) Biohazard transport bag containing double-bagged vaccine. 
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APPENDIX D 
 
Fluorescence-based bacterial viability kit (LIVE/DEAD® BacLight. Bacterial 
Viability, kit L7012, protocol adapted from manufacturer’s instructions, Life 
Technology, Molecular Probes, Eugene, OR, USA) 
 
Contents 
- SYTO 9 dye, 3.34 mM (Component A), 300 µL solution in DMSO 
- Propidium iodide, 20 mM (Component B), 300 µL solution in DMSO 
Storage and Handling:  
- DMSO stock solutions should be stored frozen at ≤–20°C and protected from light. 
- Allow reagents to warm to room temperature and centrifuge briefly before opening the 
vials. Before refreezing, seal all vials tightly. When stored properly, these stock 
solutions are stable for at least one year.  
 
1. Grow 30 mL cultures of Rhodococcus equi to late log phase in nutrient broth. 
2. Concentrate 25 mL of the bacterial culture by centrifugation at 10,000 × g for 10–15 
minutes. 
3. Remove the supernatant and resuspend the pellet in 2 mL of PBS. 
4. Add 1 mL of this suspension to each of two 50 mL centrifuge tubes containing either 
20 mL of PBS (intact bacteria tube) or 20 mL of 70% isopropyl alcohol (damaged 
bacteria tube). 
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5. Incubate both samples at RT for 1 hour, mixing every 15 minutes. 
6. Pellet both samples by centrifugation at 10,000 × g for 10–15 minutes. 
7. Resuspend the pellets in 20 mL of PBS and centrifuge again as in step 6. 
8. Resuspend both pellets in separate tubes with 10 mL of PBS. 
9. Determine the optical density at 670 nm (OD670) of a 3 mL aliquot of the bacterial 
suspensions in acrylic absorption cuvettes (1 cm pathlength). 
10. Dilute suspension in PBS to reach OD of 0.4. 
11. Mix five different proportions of R. equi according to (table below) in 16 × 125 mm 
borosilicate glass culture tubes. The total volume of each of the five samples will be 
2 ml. 
 
 
 
Table D-1  
Volume of cell suspension for each ratio undamaged:damaged cells 
 
Ratio of 
undamaged:damaged cells 
Volume (ml) intact-cell 
suspension 
Volume (ml) damaged-
cell suspension 
0:100 0 2.0 
10:90 0.2 1.8 
50:50 1.0 1.0 
90:10 1.8 0.2 
100:0 2.0 0 
 
 
 
 
 
12. Mix 6 µL of Component A with 6 µL of Component B in a microfuge tube. 
13. Prepare a 2X stain solution by adding the entire 12 µL of the above mixture to 2.0 
mL of filter-sterilized dH2O in a 16 × 125 mm borosilicate glass culture tube and mix 
well. 
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14. Pipet 100 µL of each of the bacterial cell suspension mixtures into separate wells of a 
96-well flat-bottom microplate. 
15. Using a new tip for each well, pipet 100 µL of the 2X staining solution (from step 
7.4) to each well and mix thoroughly by pipetting up and down several times. 
16. Incubate at room temperature in the dark for 15 minutes. 
17. With the excitation wavelength centered at about 485 nm, measure the fluorescence 
intensity at a wavelength centered at about 530 nm (emission 1; green) for each well 
of the entire plate. 
18. With the excitation wavelength still centered at about 485 nm, measure the 
fluorescence intensity at a wavelength centered about 630 nm (emission 2; red) for 
each well of the entire plate. 
19. Analyze the data by dividing the fluorescence intensity of the stained bacterial 
suspensions (F cell) at emission 1 by the fluorescence intensity at emission 2  
20. Record the data and save it for subsequent analysis. 
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APPENDIX E 
 
 
Protocol for isolation and culture of peripheral blood mononuclear cells (PBMCs) 
using Carbonyl-iron and Ficoll-Paque (modified from the original protocol kindly 
provided by Dr. Julia Felippe, Cornell University, Ithaca, NY) 
 
1. Collect blood in heparinized tubes. 
2. Allow samples to stand at RT until plasma separates from red cells (no more than 30 
min). 
3. Under the hood, pipet plasma to sterile 50 ml conical tubes containing 600 mg sterile 
CN-Fe. 
4. Incubate tubes in a rotator at 37o C. 
5. Remove plasma off the CN-Fe with a magnet (run magnet around the tube to attract 
iron a few times; then pour plasma into a fresh tube slowly, holding the magnet 
outside the lower wall of the tube, close to the opening). 
6. Centrifuge plasma at 300 × g, 4o C, 10 min. 
7. Discard supernatant. 
8. Resuspend pellet in 8 ml cold PBS. 
9. Aliquot 4 ml of Ficoll 1077 in 12 ml tubes [use the proportion 2:1 (cell suspension: 
Ficoll)]. 
10. Layer 8ml of the cell suspension over Ficoll, carefully. 
11. Centrifuge tubes at 700 × g, RT, 15 min. 
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12. Transfer the cloudy interface layer between Ficoll and suspension into a clean 15 
conical tube. 
13. Add cold PBS to the capacity of the tube. 
14. Centrifuge tubes at 1200 rpm, 4o C, 10 min. 
15. Aspirate (discard) supernatant. 
16. Wash the cell pellet 3 times with 12 ml cold PBS. 
17. Resuspend the final cell pellet in 2 ml PBS – count cells. 
18. Stimulate 1x106 cells with antigen (vaccine, MOI 10) or mitogen (ConA final 
concentration 5mcg/ml, stock 0.5 mg/ml, use 10 µl/ml of culture) in culture medium 
(RPMI + 15% fetal bovine serum and 1.5% penicillin-streptomycin). 
19. Incubate plate at 37o C, 5% CO2 for 48 h. 
20. Harvest supernatant in 2 ml tubes. 
21. Store in -80oC until assayed. 
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APPENDIX F 
 
 
 
Protocol for IFN-γ ELISA in supernatant of cultured PBMCs, modified from 
manufacturer’s instructions (product code 3117-1H-6, Mabtech Inc., Cincinnati, OH, 
USA) 
 
1. Coat a high protein binding ELISA plate with mAb bIFN-γ, diluted to 2 µg/ml in 
PBS, pH 7.4, by adding 100 µl/well. Incubate overnight at 4-8oC. 
2. Wash twice with PBS (200 µl/well). 
3. Block plate by adding 200 µl/well of incubation buffer. 
4. Wash five times with PBS containing 0.05% Tween. 
5. Prepare equine IFN-g standard by reconstituting contents of vial 4 in 1 ml PBS with 
1% BSA and leave at RT for 15 minutes, then vortex the tube and spin down. This 
gives a concentration of 0.2 µg/ml. Use immediately or store in aliquots at -20oC for 
future use. We recommend the aliquots not to be refrozen after initial use. For the 
test, prepare dilutions of the stock using the standard range as a guideline. 
6. Add 100 µl/well of samples or standards diluted in incubation buffer and incubate for 
2 hours at RT. 
7. Wash as in step 4. 
8. Add 100 µl/well of mAb PAN-biotin at 0.1 µg/ml in incubation buffer. Incubate for 1 
hour at RT. 
9. Wash as in step 4. 
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10. Add 100 µl/well of Streptavidin-HRP diluted in 1:1000 in incubation buffer. 
Incubate for 1 hour at RT.  
11. Wash as in step 4. 
12. Add 100 µl/well of TMB substrate solution. 
13. Add 100 µl/well of stop solution. 
14. Measure the optical density in a microplate reader at 450 nm. 
 
Reagents 
Incubation buffer: PBS with 0.05% Tween 20 with 0.1% BSA 
TMB substrate solution: ready to use substrate (Bethyl Laboratories, Montgomery, TX, 
USA) 
Stop solution: 0.18M H2SO4  
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APPENDIX G 
 
 
 
Protocol for total immunoglobulin ELISA determination (protocol from Bethyl 
Laboratories, Inc., Montgomery, TX) 
 
1. Add 100 mcl of diluted coating antibody to each well. 
1. Note: Run each standard or sample in duplicate. 
2. Incubate at room temperature (20-25° C) for 1 hour. 
3. Wash plate FIVE times. 
4. Add 200 mcl of Blocking Solution to each well. 
5. Incubate at room temperature for 30 minutes. 
6. Wash plate FIVE times. 
7. Add 100 mcl of standard or sample to well. 
8. Incubate at room temperature for 1 hour. 
9. Wash plate FIVE times. 
10. Add 100 mcl of diluted HRP detection antibody to each well (See table below). 
11. Incubate at room temperature for 1 hour. 
12. Wash plate FIVE times. 
13. Add 100 mcl of TMB Substrate Solution to each well. 
14. Develop the plate in the dark at room temperature for 15 minutes. 
15. Stop reaction by adding 100 mcl of Stop Solution to each well. 
16. Measure absorbance on a plate reader at 450 nm. 
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Table G-1  
Sources of polyclonal antibodies against horse immunoglobulins 
 
Immunoglobulin isotype HRP detection polyclonal antibody source 
IgA Goat 
IgG1 Goat 
IgG4/7 Sheep 
IgG3/5 Goat 
 
 
 
 
 
Reagents 
Blocking buffer: 1% BSA in 1x room temperature PBS 
Washing buffer: 1x PBS with 0.5% Tween 20 
Stop solution: 0.18 M H2SO4.  
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APPENDIX H 
 
 
 
Protocol for Rhodococcus equi-specific immunoglobulin ELISA (modified from 
the original protocol kindly provided by Dr. Steeve Giguère from University of Georgia, 
Athens, GA) 
 
1. To make coating buffer, empty contents of one capsule of carbonate-bicarbonate 
buffer (Sigma-Aldrich, St. Louis, MO, USA) into 100 ml of deionized water.  Mix 
until dissolved.  Dilute 2.5 µg/ml of R. equi lysate in fresh coating buffer to desired 
concentration and put 100µl per well(s) in your ELISA plate(s). Put sealing cover 
over the wells and store overnight at 4°C. 
2. Prepare blocking solution.  
3. Take plate from 4°C and remove protein/coating buffer solution from the wells.   
4. Wash plate 4 times with washing buffer.  
5. Block the plate using 300µl/well of the blocking solution.  Reseal plate and let sit at 
room temperature for 60 minutes.   
6. Wash plate 4 times with washing buffer. 
7. Apply 100µl/well of anti-equine Ig (see table below for specific information about 
the antibody). Allow plate to incubate at RT for 60 minutes.   
8. Wash plate 4 times with washing buffer. 
9. Apply 100µl/well of the substrate solution to your plate and cover the plate.  
Incubate the plate in the dark for 15 min. 
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10. Add 100µl/well of stop solution to the wells. 
11. Measure absorbance on a microplate reader at 450 nm.  
Reagents 
Blocking buffer: 1% BSA in 1x room temperature PBS 
Washing buffer: 1x PBS with 0.5% Tween 20  
Stop solution: 0.18 M H2SO4.  
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APPENDIX I 
 
 
 
Protocol for antigen production for Rhodococcus equi-specific ELISA (modified 
from the original protocol kindly provided by Dr. Steeve Giguère from University of 
Georgia, Athens, GA) 
 
1. Inoculate BHI plates with R. equi 5-331. 
2. Incubate at 37°C for 48 hours. 
3. Select one colony from plates and inoculate 250mls BHI broth in a 500 ml 
Erlenmeyer flask. 
4. Place in shaker with a speed of 160 RPMs at 37°C for 48 hours. 
5. Aliquot broth into 50ml centrifuge tubes 
6. Centrifuge at 3840 × g (500 RPMs) for 10 min. 
7. Decant off supernatant, retaining the pellet. 
8. Resuspend pellet with 100 ml PBS. 
9. Centrifuge at 3840 × g for 10 min 
10. Decant off supernatant and resuspend in remainder fluid. 
11. Take 2mls and add to 10 ml of PBS. 
12. Do three freeze/thaw cycles by freezing at -80°C and thawing in 37°C water bath. 
13. Centrifuge at 12,000 × g (10,000 RPMs) for 15 min at 4°C. 
14. SAVE SUPERNATANT 
15. Centrifuge supernatant at 25,000 × g (14,500 RPMs) for 20 min at 4°C. 
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16. Place on ice and test for protein concentration with BCA protein assay kit (Pierce) 
using microplate technique and read in the microplate reader at 540nm.  Working 
reagent 10mls of part A to 200µl of part B. 
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APPENDIX J 
 
 
 
Primary data from IFN-γ production on cultured PBMCs (median and range) of 
vaccinated foals on both day2 2 and 32 of life. 
 
 
 
 
Table J-1 
IFN-γ (pg/ml) production median (range) on cultured PBMCs from vaccinated foals on 
days 2 and 32 of life. 
 
Group IFN-γ (pg/ml) Day 2 Day 32 
Saline Control 13.9 (0 to 2,211) 854.9 (200.5 to 56,893.2) 
EBRE 1 0 (0 to 66.7) 16,399.8 (3,086.98 to 77,480.1) 
EBRE 2 0 (0 to 47.6) 3,145.4 (81.1 to 9,221.4) 
LVRE 0 (0 to 14.8) 6,065.4 (1,637.4 to 12,766.9) 
  
  
 
126 
APPENDIX K 
 
 
 
Primary data from serum antibody levels of vaccinated foals on both day 2 and day 32 of 
life. 
 
 
 
Table K-1 
Distribution of total IgA (ng/ml) from serum by group and age: median (range)  
 
Group Total IgA Day 2 Day 32 
Saline Control 234,230 (79,731 – 762,820) 145,758 (24,852 – 1,176,302) 
EBRE 1 735,818 (377,076 – 2,098,880) 86,292 (29,078 – 536,244) 
EBRE 2 509,942 (101,067 – 2,033,148) 223,511 (24,693 – 498,557) 
LVRE 582,256 (170,958 – 1,876,689) 302,229 (43,604 – 715,973) 
 
 
 
Table K-2  
Distribution of Total IgG1 (ng/ml) from serum by group and age: median (range) 
 
Group Total IgG1 Day 2 Day 32 
Saline Control 4,692,804 (2,448,892 – 6,026,232) 3,321,586 (1,985,946 – 13,752,336) 
EBRE 1 3,569,435 (1,534,894 – 6,460,604) 3,269,665 (1,757,995 – 8,768,651) 
EBRE 2 4,917,821 (2,271,937 – 8,404,795) 5,171,167 (2,787,443 – 8,941,273) 
LVRE 10,279,961 (3,363,242 – 13,752,336) 8,703,443 (6,155,403 –11,921,392) 
 
 
 
Table K-3  
Distribution of Total IgG4/7 (ng/ml) from serum by group and age: median (range) 
 
 Total IgG4/7 
Group Day 2 Day 32 
Saline Control 7,952,728 (852,402– 10,292,461) 3,659,334 (529,879 – 6,461,719) 
EBRE 1 4,608,000 (1,256,550 – 14,398,587) 2,609,406 (884,535 – 6,934,430) 
EBRE 2 8,408,957 (4,355,850 – 15,101,657) 3,285,647 (2,596,798 – 5,656,674) 
LVRE 10,950,509 (7,461,929 – 15,222,571) 5,724,701 (2,734,293– 8,027,475) 
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Table K-4  
Distribution of Total IgG G3/5 (ng/ml) from serum by group and age: median (range) 
 
 Total IgG3/5 
Group Day 2 Day 32 
Saline Control 3,062,260 (1,007,223– 4,927,078) 1,819,580 (623,153– 9,058,173) 
EBRE 1 1,839,858  (1,282,800 – 5,549,351) 1,409,532 (1,048,560 – 2,632,221) 
EBRE 2 2,616,035 (775,120 – 6,566,822) 1,435,738 (556,940 –3,189,244) 
LVRE 6,453,936 (1,938,040 – 13,001,753) 3,305,300 (1,684,840 – 5,948,785) 
 
 
 
Table K-5  
Distribution of R. equi-specific IgA from serum by group and age: median (range) ratio 
OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgA Day 2 Day 32 
Saline Control 0.9 (0.4 – 2.1) 0.1 (0.1 – 0.6) 
EBRE 1 1.1 (0.4 – 2.1) 0.2 (0.1 – 1.0) 
EBRE 2 0.8 (0.5 – 1.4) 0.1 (0.1 – 1.0) 
LVRE 0.8 (0.5 – 1.4) 0.2 (0.1 – 0.9) 
 
 
 
Table K-6  
Distribution of R. equi-specific IgG1 from serum by group and age: median (range) ratio 
OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgG1 Day 2 Day 32 
Saline Control 0.8 (0.2 – 0.9) 0.5 (0.3 – 2.3) 
EBRE 1 0.7 (0.5 – 1.1) 0.5 (0.3 – 0.9) 
EBRE 2 0.6 (0.5 – 1.7) 0.6 (0.4 – 0.9) 
LVRE 0.7 (0.2 – 1.3) 1.3 (0.8 – 1.5) 
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Table K-7 
Distribution of R. equi-specific IgG4/7 from serum by group and age: median (range) 
ratio OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgG4/7 Day 2 Day 32 
Saline Control 0.5 (0.1 – 0.9) 0.3 (0.1 – 1.1) 
EBRE 1 0.5 (0.2 – 0.6) 0.2 (0.1 – 0.5) 
EBRE 2 0.5 (0.2 – 0.8) 0.2 (0.1 – 0.5) 
LVRE 0.3 (0.2 – 0.8) 0.4 (0.2 – 0.7) 
 
 
 
Table K-8 
Distribution of R. equi-specific IgG3/5 from serum by group and age: median (range) 
ratio OD sample (- negative control)/OD positive (- negative control) 
 
 
 
Group R. equi-specific IgG3/5 Day 2 Day 32 
Saline Control 0.3 (0.1 – 1.3) 0.2 (0.1 – 2.0) 
EBRE 1 0.7 (0.2 – 0.6) 0.4 (0.1 – 1.2) 
EBRE 2 0.6 (0.2 – 1.7) 0.3 (0.2 – 0.8) 
LVRE 0.4 (0.2 – 0.9) 0.5 (0.3 – 0.8) 
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APPENDIX L 
 
 
 
Results from naso-pharyngeal antibody levels of vaccinated foals on both day 2 and day 
32 of life. 
 
Table L-1 
Distribution of Total IgA (ng/ml) from NP eluates by Group and age: median (range) 
 
Group Total IgA Day 2 Day 32 
Saline Control 7,294 (1,887 – 19,052) 30,377 (7,444 – 377,659) 
EBRE 1 6,325 (3,550 – 17,107) 17,798 (11,973 – 80,645) 
EBRE 2 3,187 (890 – 14,876) 43,153 (10,065 – 103,359) 
LVRE 4,091 (835 – 19,112) 21,479 (6,330 – 76,775) 
 
 
 
Table L-2 
Distribution of R. equi-specific IgA from Nasal Swabs by Group and age: median 
(range) ratio OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgA Day 2 Day 32 
Saline Control 39.7 (0.3 – 81.9) 44.3 (3.7 – 741.2) 
EBRE 1 10.5 (1.5 – 172.4) 14.6 (1.3 – 524.9) 
EBRE 2 16.0 (6.0 – 163.5) 98.6 (16.5 – 908.4) 
LVRE 16.6 (3.4 – 90.6) 77.1 (11.1 – 676.8) 
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APPENDIX M 
 
 
 
Results from BAL fluid antibody levels of vaccinated foals on both day 2 and day 32 of 
life. 
 
Table M-1 
Distribution of Total IgA (ng/ml) from BAL fluid by group and age: median (range) 
adjusted to urea values 
 
Group Total IgA (ng/ml) Day 2 Day 32 
Saline Control 106.5 (22.1 – 262.7) 2,342.5 (928.4 – 17,527.8) 
EBRE 1 61.5 (36.7 – 355.5) 1,374.0 (353.2 – 3,787.7) 
EBRE 2 113.4 (17.3 – 1,040.6) 3,142.9 (26.8 – 10,883.6) 
LVRE 190.6 (48.8 – 798.4) 1,014.4 (79.2 – 1,778.3) 
 
 
 
Table M-2 
Distribution of Total IgG1 (ng/ml) from BAL fluid by group and age: median (range) 
adjusted to urea values 
 
Group Total IgG1 (ng/ml) Day 2 Day 32 
Saline Control 774.4 (24.1 – 10,086.3) 2,688.0 (990.7 – 19,249.6) 
EBRE 1 2,243.6 (635.6 – 12,436.5) 2,099.5 (130.0 – 8055.2) 
EBRE 2 3,442.4 (1.0 – 7,324.0) 5,394.9 (1,602.6 – 26,860.0) 
LVRE 4,765.0 (1.0 – 26,860.0) 16,325.7 (2,896.4 – 26,860.0) 
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Table M-3 
Distribution of Total IgG4/7 (ng/ml) from BAL fluid by group and age: median (range) 
adjusted to urea values 
 
Group Total IgG4/7 (ng/ml) Day 2 Day 32 
Saline Control 792.8 (2.6 – 6,412.6) 4,789.0 (1,738.2 – 16,608.0) 
EBRE 1 1,823.9 (820.6 – 4,108.7) 3,223.5 (662.9 – 15,992.5) 
EBRE 2 831.3 (4.9 – 4,089.3) 5,766.9 (248.8 – 14,445.7) 
LVRE 1,719.5 (7.3 – 6,725.9) 1,197.9 (280.0 – 9,395.4) 
 
 
 
Table M-4 
Distribution of Total IgG G3/5 (ng/ml) from BAL fluid by group and age: median (range) 
adjusted to urea values 
 
Group Total IgG3/5 (ng/ml) Day 2 Day 32 
Saline Control 388.6 (2.6 to 2,082.7) 1,724.8 (598.3 – 11,169.9) 
EBRE 1 510.3 (226.1 – 1,884.1) 1,877.8 (185.0 – 3,309.2) 
EBRE 2 207.0 (4.9 – 1,015.4) 1,926.4 (50.2 – 5,118.1) 
LVRE 892.4 (7.3 – 2,301.3) 1,297.4 (500.9 – 2,671.2) 
 
 
 
Table M-5 
Distribution of R. equi-specific IgA from BAL fluid by group and age: median (range) 
ratio of OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgA Day 2 Day 32 
Saline Control <0.01 (<0.01 – 0.08) 0.07 (0.02 – 0.23) 
EBRE 1 <0.01 (<0.01 – 0.09) 0.04 (<0.01 – 0.15) 
EBRE 2 <0.01 (<0.01 –  0.02 0.04 (<0.01 – 0.12) 
LVRE <0.01 (<0.01 – 0.01) 0.02 (<0.01 – 0.08) 
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Table M-6 
Distribution of R. equi-specific IgG1 from BAL fluid by group and age: median (range) 
ratio of OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgG1 Day 2 Day 32 
Saline Control 0.02 (0.00 – 0.21) 0.06 (0.01 – 0.31) 
EBRE 1 0.08 (0.00 – 0.24) 0.01 (0.00 – 0.43) 
EBRE 2 0.02 (0.00 –  0.51) 0.04 (<0.01 – 0.15) 
LVRE 0.04 (0.00 – 0.26) 0.12 (<0.01 – 0.24) 
 
 
Table M-7 
Distribution of R. equi-specific IgG4/7 from BAL fluid by group and age: median (range) 
ratio of OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgG4/7 Day 2 Day 32 
Saline Control 0.05 (0.01 – 0.28) 0.21 (0.04 – 0.46) 
EBRE 1 0.10 (0.03 – 0.56) 0.19 (0.01 – 0.79) 
EBRE 2 0.05 (0.00 – 1.36) 0.09 (0.02 – 1.37) 
LVRE 0.06 (0.00 – 0.44) 0.07 (<0.01 – 0.34) 
 
 
 
Table M-8 
Distribution of R. equi-specific IgG3/5 from BAL fluid by group and age: median (range) 
ratio of OD sample (- negative control)/OD positive (- negative control) 
 
Group R. equi-specific IgG3/5 Day 2 Day 32 
Saline Control 0.85 (0.01 – 3.81) 2.63 (0.16 – 5.07) 
EBRE 1 3.36 (0.74 – 4.98) 3.38 (0.22 – 8.59) 
EBRE 2 0.98 (0.02 – 4.60) 3.04 (0.56 – 5.04) 
LVRE 0.16 (0.01 – 2.15) 0.12 (0.10 – 2.64) 
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APPENDIX N 
 
 
 
I. Summary of Data Analysis of Mare Serum and Milk Values 
A. Data: Data are Mares12 
B. Methods: Association between immunoglobulin concentrations in serum and 
milk for the 34 mares was made using linear regression analysis.  When appropriate, 
data were logarithmically (base 10) transformed to ensure assumptions of linear 
modeling were not violated.  Comparisons of immunoglobulin concentrations among 
treatment groups were performed using Kruskal-Wallis testing.  
C. Results: 
1. General summary: All mares had detectable Ig of all classes in both milk and 
serum, and all mares had detectable Ig specific against R. equi in milk and serum.  There 
was significant correlation between milk and serum for total and R. equi-specific IgA, 
IgG1, IgG4/7, and IgG3/5 except for total concentrations of IgG1 and IgG4/7; correlations 
were generally moderate in magnitude (Table N-1).  There were no significant 
differences among treatment groups in milk concentrations of IgA, IgG1, IgG4/7, or 
IgG3/5 against R. equi.   
For all isotypes for both total and R. equi-specific antibodies, concentrations 
were higher in serum than in milk (Table N-2).  Total isotype distribution was relatively 
similar in milk, although IgG4/7 and IgG3/5 tended to be higher in serum.  R. equi-specific 
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concentrations of IgA were relatively higher and concentrations of IgG4/7 were relatively 
lower in both milk and serum (Table N-2).   
 
 
 
Table N-1 
R-squared values and P values for correlations between milk and serum for total and  
R. equi-specific immunoglobulins among 34 mares 
 
Isotype     R-squared  P value 
IgA  
  Total      0.31   0.0010 
  R. equi-specific     0.65   < 0.0001 
   
IgG1 
  Total      0.09   0.0798 
  R. equi-specific     0.37   0.0001 
 
IgG4/7 
  Total      0.05   0.2019 
  R. equi-specific     0.44   < 0.0001 
 
IgG3/5 
  Total      0.26   0.0021 
  R. equi-specific     0.56   < 0.0001  
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Table N-2 
Median (range) of concentrations of immunoglobulins in milk and serum 
 
a. Total (x 103; ng/ml) 
 
Source IgA IgG1 IgG4/7 IgG3/5 
Milk 511 (193-1,049) 646 (312-2,098) 724 (341-2,098) 590  (191-1,290) 
Serum 1,390 (587-6,711) 1,970 (784-4,274) 7,640 (2,592-5,169) 7,843 (3,724-16,507) 
 
 
 
b. R. equi-specific ratio of OD sample (- negative control)/OD positive (- negative 
control) 
 
Source IgA IgG1      IgG4/7        IgG3/5 
Milk 2,382 (408-10,499) 107 (17-1,234) 10 (1-34) 80 (15-20,990) 
Serum 15,424 (4,634-67,197) 536 (175-5,742) 73 (16-963) 2,417 (70 to 182,902) 
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Fig. N-1. Total IgA 
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Fig. N-2.Specific IgA  
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Fig. N-3.Total IgG1 (not significant) 
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Fig. N-4.Specific IgG1 
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Fig. N-5.Total IgG4/7 (not significant) 
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Fig. N-6.Specific IgG4/7 
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Fig. N-7.Total IgG3/5 
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Fig. N-8.Specific IgG3/5 
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APPENDIX O 
 
 
 
I. Association of mare milk concentrations with foal serum concentrations 
A. Data: Data are MFS13 
B. Methods: Association between immunoglobulin concentrations in mares milk 
and foal serum were performed for the 34 mare-foal pairs.  When appropriate, data were 
logarithmically (base 10) transformed to ensure assumptions of linear modeling were not 
violated.  Comparisons of milk immunoglobulin concentrations among treatment groups 
were performed using Kruskal-Wallis testing.   
C. Results: 
General summary: In general, total immunoglobulin was either significantly  
(P < 0.05 for IgA) or tended (0.05 < P < 0.11 for IgG4/7 and IgG3/5) weak positive 
association between milk and foal serum on day 2, except for IgG1.  For day 32 and the 
ratio, there was no significant positive association between mare’s milk and foal’s serum 
values.  For R. equi-specific concentrations, all isotypes except IgG1 (P = 0.1345) were 
significantly (P < 0.05) positively correlated with mare milk concentration on Day 2.  
For IgG4/7 and IgG3/5, this association was also significant on day 32.  There was no 
significant difference among treatment groups in milk concentrations of R. equi-specific 
antibodies for any isotypes, but there were a couple of the totals that did differ 
significantly BEFORE adjusting for multiple comparisons.  
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1. IgA:  
 a. Total IgA: There was no significant association of IgA on days 2, 31, 
or the ratio of Day 32:Day 2 (Table O-1; only log-transformed data shown because these 
best fit the data).  There was no difference among treatment groups in mare’s milk 
concentration of total IgA (P = 0.5019; data not shown).   
 b. R. equi-specific IgA: There was modest but significant association of 
concentration of R. equi-specific IgA in milk with serum on day 2, but not on day 32 or 
for the ratio of Day 32:Day 2 (Table O-2). There was no difference among treatment 
groups in mare’s milk concentration of total IgA (P = 0.5269; data not shown).   
2. IgG1:  
 a. Total IgG1: There was no significant association of IgG1 on Day 2, or 
for the ratio of Day 32:Day 2 (Table O-3; only log-transformed data shown because 
these best fit the data).   There was a significant NEGATIVE association of mare’s milk 
IgG1 and foal serum IgG1 on day 32. There was no difference among treatment groups in 
mare’s milk concentration of total IgG1 (P = 0.0443; data not shown). When adjusting 
for multiple comparisons it is not significant. 
 b. R. equi-specific IgG1: There was no significant association of 
concentration of R. equi-specific IgG1 in milk with serum on Day 2 or Day 32, and there 
was a significant correlation between the mare’s milk concentration and the ratio of Day 
32:Day 2 (Table O-4). There was no difference among treatment groups in mare’s milk 
concentration of total IgA (P = 0.6256; data not shown).  When adjusting for multiple 
comparisons it is not significant. 
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3. IgG4/7:  
 a. Total IgG4/7: There was no significant association of IgG4/7 on Day 2, 
Day 32, or for the ratio of Day 32:Day 2 (Table O-5; only log-transformed data shown).   
There was no difference among treatment groups in mare’s milk concentration of total 
IgG4/7 (P = 0.3157; data not shown).  
 b. R. equi-specific IgG4/7: There was significant association of 
concentration of R. equi-specific IgG4/7 in milk with serum on Day 2 and Day 32, but 
there was not a significant correlation between the mare’s milk concentration and the 
ratio of Day 32:Day 2 (Table O-6). There was no difference among treatment groups in 
mare’s milk concentration of total Ig4/7 (P = 0.2612; data not shown. 
4. IgG3/5:  
 a. Total IgG3/5: There was no significant association of IgG3/5 on Day 2, 
Day 32, or for the ratio of Day 32:Day 2 (Table O-5; only log-transformed data shown).   
There was a significant difference among treatment groups in mare’s milk concentration 
of total IgG3/5 (P = 0.0246; data not shown).  When adjusting for multiple comparisons it 
is not significant 
 b. R. equi-specific IgG3/5: There was significant association of 
concentration of R. equi-specific IgG3/5 in milk with serum on Day 2 and Day 32, but 
there was not a significant correlation between the mare’s milk concentration and the 
ratio of Day 32:Day 2 (Table O-6). There was no difference among treatment groups in 
mare’s milk concentration of total IgA (P = 0.2612; data not shown).   
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Table O-1 
Association of total IgA in mare’s milk with foal serum IgA on day 2, day 32, and the 
ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.15 0.0457   0.3063 (-0.1774 to 0.7900) 
  Day 32   0.04 0.2698   0.2833 (-0.2131 to 0.7798) 
  Ratio Day 32: Day 2  <0.01 0.9407   0.0230 (-0.5793 to 0.6253) 
 
 
 
Table O-2 
Association of R. equi-specific IgA in mare’s milk with foal serum IgA samples on day 
2, day 32, and the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.41 <0.0001  0.8567 (0.5029 to 1.2105) 
  Day 32   0.04 0.2388   0.5098 (-0.3220 to 1.3416) 
  Ratio Day 32: Day 2  0.03 0.3286   -0.3584 (-1.0662 to 0.3494) 
 
 
 
Table O-3 
Association of total IgG1 in mare’s milk with foal serum IgG1 on day 2, day 32, and the 
ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.03 0.3423   -0.1685 (-0.5111 to 0.1741) 
  Day 32   0.18 0.0120   -0.3927 (-0.6816 to -0.1038) 
  Ratio Day 32: Day 2  0.06 0.1808   -0.2242 (-0.5454 to 0.0970) 
 
 
 
Table O-4 
Association of R. equi-specific IgG1 in mare’s milk with foal serum IgG1 samples on day 
2, day 32, and the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.07 0.1345   0.2700 (-0.0746 to 0.6146) 
  Day 32   0.06 0.1495   -0.4859 (-1.1307 to 0.1589) 
  Ratio Day 32: Day 2  0.15 0.0221   -0.7558 (-1.3716 to -0.1400) 
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Table O-5 
Association of total IgG4/7 in mare’s milk with foal serum IgG4/7 on day 2, day 32, and 
the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.08 0.1050   0.4153 (-0.0727 to 0.9033) 
  Day 32   0.02 0.3664   0.2526 (-0.2878 to 0.7930) 
  Ratio Day 32: Day 2  0.04 0.2860   -0.1627 (-0.4567 to 0.1313) 
 
 
 
Table O-6 
Association of R. equi-specific IgG 4/7 in mare’s milk with foal serum IgG4/7 samples on 
day 2, day 32, and the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.52 <0.0001  0.7416 (0.4938 to 0.9893) 
  Day 32   0.29 0.0010   0.6717 (0.3081 to 1.0353) 
  Ratio Day 32: Day 2  <0.01 0.6248   -0.0699 (-0.3474 to 0.2076) 
 
 
 
Table O-7 
Association of total IgG3/5 in mare’s milk with foal serum IgG 3/5 on day 2, day 32, and 
the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.08 0.0837   0.3558 (-0.0344 to 0.7460) 
  Day 32   0.03 0.3085   0.2062 (-0.1844 to 0.5968) 
  Ratio Day 32: Day 2  0.06 0.1591   -0.1513 (-0.0543 to 0.3569) 
 
 
 
Table O-8 
Association of R. equi-specific IgG3/5 in mare’s milk with foal serum IgG3/5 samples on 
day 2, day 32, and the ratio of day 32:2 (log10-transformed data) 
 
Foal sample   R2 P value   Slope (95% CI) 
  Day 2    0.44 <0.0001  0.6407 (0.3879 to 0.8935) 
  Day 32   0.19 0.0097   0.5681 (0.1634 to 0.9728) 
  Ratio Day 32: Day 2  <0.01 0.6967   -0.0752 (-0.4501 to 0.2997) 
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Fig. O-1. IgA (total) on Day 2 in foal serum versus mare’s milk.  Weak and non-
significant association.   
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Fig. O-2. IgA specific for R. equi in foal serum versus mare’s milk on Day 2.  The 
association was weak but statistically significant.   
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Fig. O-3. IgG 1 specific for R. equi in foal serum versus mare’s milk on Day 2.  The 
association was weak and not statistically significant (P = 0.1345) 
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Fig. O-4. IgG4/7 specific for R. equi in foal serum versus mare’s milk on Day 2.  The 
association was weak and not statistically significant (P < 0.0001) 
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Fig. O-5. IgG3/5 specific for R. equi in foal serum versus mare’s milk on Day 2.  The 
association was weak but statistically significant (P < 0.0001) 
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APPENDIX P 
 
 
 
I. Association of Mare Milk IgA and Nasal IgA 
A. Data are MFIGA in U:\Infectious Diseases\Requi\Vaccine\Data 2012\Mare 
Milk and Serum 
B. Analysis by linear regression; data log10-transformed as appropriate 
C. Results:  
1. Total IgA: There was a moderate but significant correlation between mares 
milk IgA concentration and total nasal IgA detected on day 2 but not on day 32 or for the 
ratio of day 32 to day 2 (Table P-1; Fig. 1-6).   There was no significant effect of 
treatment group or significant interaction of treatment group and foal sample (data not 
shown).  
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Table P-1 
Association of total IgA in mare’s milk with foal nasal IgA samples on day 2, day 32, 
and the ratio of day 32:2.   
 
a. Raw data 
 
Foal sample   R2 P value  Slope (95% CI) 
  Day 2    0.33 0.0004   0.0142 (0.0071 to 0.0212) 
  Day 32   0.07 0.1414   0.08 (-0.03 to 0.19) 
  Ratio Day 32: Day 2  0.01 0.5635   0.00 (-0.01 to 0.01) 
 
 
 
b. Log10-transformed data 
 
Foal sample   R2 P value  Slope (95% CI) 
  Day 2    0.27 0.0017   1.14 (0.49 to 1.79) 
  Day 32   0.15 0.0237   0.96 (0.17 to 1.75) 
  Ratio Day 32: Day 2  >0.01 0.7974   -0.14 (-1.23 to 0.95) 
 
 
 
2. Specific IgA: There was a modest but significant correlation between mares 
milk IgA concentration and total nasal IgA detected on day 2 but not on day 32 or for the 
ratio of day 32 to day 2 (Table P-2; Fig. P-7-P-12).  There was no significant effect of 
treatment group or significant interaction of treatment group and foal sample (data not 
shown). 
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Table P-2 
Association of R. equi-specific IgA in mare’s milk with foal nasal IgA samples on day 2, 
day 32, and the ratio of day 32:2.   
 
a. Raw data 
 
Foal sample   R2 P value  Slope (95% CI) 
  Day 2    0.15 0.0223   0.0054 (0.0011 to 0.0097) 
  Day 32   >0.01 0.8964   -0.0018 (-0.0292 to 0.0256)  
  Ratio Day 32: Day 2  0.02 0.4510   -0.0009 (-0.0003 to 0.0012) 
 
 
 
b. Log10-transformed data 
 
Foal sample   R2 P value  Slope (95% CI) 
  Day 2    0.12 0.0457   0.58 (0.03 to 1.13) 
  Day 32   0.04 0.2317   0.45 (- 0.28 to 1.18) 
  Ratio Day 32: Day 2  >0.01 0.7234   -0.13 (-0.84 to 0.58) 
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Fig. P-1. Total IgA Nasal vs milk day 2 
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Fig. P-2. Log10 total IgA nasal vs milk day 2 
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Fig. P-3. Total IgA nasal vs milk day 32 
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Fig. P-4. Log10 total IgA nasal vs milk day 32 
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Fig. P-5. Total IgA nasal ratio vs milk 
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Fig. P-6. Log10 total IgA nasal ratio vs milk 
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Fig. P-7. Specific IgA day 2 vs milk 
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Fig. P-8. Log10 specific IgA day 2 vs milk 
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Fig. P-9. Specific IgA day 32 vs milk 
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Fig. P-10. Log10 specific IgA day 32 vs milk 
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Fig. P-11. Specific IgA day 32:day2 vs milk 
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Fig. P-12. Log10 specific IgA day 32: day 2 vs milk 
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APPENDIX Q 
 
Table Q-1  
Median and range percentages of sequences represented in the fecal DNA of rectal swab 
samples from foals (Phylum, class, order, and family).  
 
 
 
Microbial Phylum/Class/Order/Family 2-day-old foals (N = 
37) 
30-day-old foals(N = 
37) 
P* 
Archaea.Euryarchaeota  0% (0%) 0% (0 to 0.6%) 0.0048 
 Methanobacteria 0% (0%) 0% (0 to 0.3%) 0.0280 
       Methanobacteriales 0% (0%) 0% (0 to 0.3%) 0.0924 
   Methanobacteriacae 0% (0%) 0% (0 to 0.3%) 0.1932 
 Methanomicrobia 0% (0%) 0% (0 to 0.6%) 0.1341 
       Methanomicrobiales 0% (0%) 0% (0 to 0.6%) 0.4321 
   Methanocorpusculaceae 0% (0%) 0% (0 to 0.6%) 0.9089 
Bacteria.Acidobacteria  0% (0%) 0% (0 to 0.2%) 0.9515 
 Acidobacteria 0% (0%) 0% (0 to 0.2%) 1.0000 
  Acidobacteriales 0% (0%) 0% (0 to 0.2%) 1.0000 
   Acidobacteriaceae 0% (0%) 0% (0 to 0.2%) 1.0000 
Bacteria.Actinobacteria  0.2% (0 to 4.1%) 1.2% (0 to 4.3%) 0.0048 
 Actinobacteria 0.2% (0 to 4.1%) 1.2% (0 to 4.3%) 0.0280 
  Actinomycetales 0.1% (0 to 3.4%) 0.3% (0 to 2.8%) 0.3904 
  Bifidobacteriales  0% (0 to 0.2%) 0% (0 to 0.2%) 1.0000 
  Other 0% (0 to 0.7%) 0% (0 to 1.5%) 1.0000 
 Coriobacteridae (subclass) 0% (0 to 1.5%) 0.2% (0 to 2.7%) <0.0001 
  Coriobacteriales 0% (0 to 1.5%) 0.2% (0 to 2.7%) 0.0080 
 Rubrobacteridae (subclass) 0% (0 to 0.7%) 0% (0 %) 0.9515 
  Rubrobacterales 0% (0 to 0.7%) 0% (0 %) 1.0000 
  Other order 0% (0%) 0% (0 to 0.8%) 0.0578 
   Other family 0% (0%) 0% (0 to 0.8%) 0.1190 
Bacteria.Bacteroidetes  16.7% (0 to 85.5%) 40.6% (0.2 to 87.8%) 0.0066 
 Bacteroidetes 16.7% (0 to 85.4%) 25.3% (0.1 to 80.5%)   0.5376 
      Bacteroidales 16.7% (0 to 85.4%) 25.3% (0.2 to 80.5%) 0.9515 
   Bacteroidieacae 16.7% (0 to 85.3%) 5.2% (0 to 53.3%) 1.0000 
   Porphyromonadaceae 0% (0 to 9.0%) 0.4% (0 to 16.4%) 0.0080 
    Prevotellaceae 0% (0 to 1.5%) 2.8% (0 to 63.1%) <0.0001 
   Rikenellaceae 0% (0 to 10.2%) 0% (0 to 5.8%) 0.2108 
   Other 0% (0 to 0.2%) 4.0% (0 to 18.0%) <0.0001 
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 Table Q-1 continued    
 
Flavobacteria  0% (0 to 1.2%) 0% (0 to 2.3%) 0.8167 
     Flavobacteriales 0% (0 to 1.2%) 0% (0 to 2.3%) 1.0000 
   Flavobacteriaceae 0% (0 to 1.2%) 0% (0 to 2.3%) 1.0000 
 Sphingobacteria 0% (0 to 0.2%) 0% (0 to 0.1%) 0.8167 
       Sphingobacteriales 0% (0 to 0.2%) 0% (0 to 0.1%) 0.9515 
     Crenotrichaceae 0% (0 to 0.1%) 0% (0%) 1.0000 
   Flexibacteriaceae 0% (0%) 0% (0 to 0.1%) 1.0000 
   Sphingobacteriaceae 0% (0 to 0.2%) 0% (0%) 1.0000 
 Other class 0% (0 to 1.7%) 5.5% (0 to 48.1%) <0.0001 
  Other order 0% (0 to 1.7%) 5.5% (0 to 48.1%) <0.0001 
   Other family 0% (0 to 1.7%) 5.5% (0 to 48.1%) <0.0001 
Bacteria.Chlamydiae  0% (0%) 0% (0 to 30.1%) <0.0001 
   Chlamydiae 0% (0%) 0% (0 to 30.1%) <0.0001 
  Chlamydiales 0% (0%) 0% (0 to 30.1%) <0.0001 
   Chlamydiaceae 0% (0%) 0.1% (0 to 30.1%) <0.0001 
   Parachlamydiaceae 0% (0%) 0% (0 to 0.1%) 1.0000 
Bacteria.Chloroflexi  0% (0%) 0% (0 to 0.2%) 0.0441 
 Anaerolineae 0% (0%) 0% (0 to 0.2%) 0.2254 
 Caldilineae  0% (0%) 0% (0 to 0.2%) 0.9515 
  Caldilineales 0% (0%) 0% (0 to 0.2%) 1.0000 
  Other  0% (0%) 0% (0 to 0.2%) 0.2635 
   Other family 0% (0%) 0% (0 to 0.2%) 0.5355 
Bacteria.Cyanobacteria  0% (0%) 0% (0 to 0.1%) 0.9515 
 Cyanobacteria 0% (0%) 0% (0 to 0.1%) 1.0000 
  Other order 0% (0%) 0% (0 to 0.1%) 1.0000 
   Other family 0% (0%) 0% (0 to 0.1%) 1.0000 
Bacteria.Deferribacteres  0% (0% to 0.2%) 0% (0 to 0.2%) 0.9515 
 Deferribacteres 0% (0% to 0.2%) 0% (0 to 0.2%) 1.0000 
  Deferribacterales 0% (0% to 0.2%) 0% (0 to 0.2%) 1.0000 
   Deferribacteraceae 0% (0%) 0% (0%) NP 
   Incertae sedis 3 0% (0 to 0.2%) 0% (0 to 0.2%) 1.0000 
Bacteria.Fibrobacteres  0% (0%) 0% (0 to 0.7%) 0.2104 
 Fibrobacteres 0% (0% to 0.2%) 0% (0 to 0.7%) 0.4698 
  Fibrobacterales 0% (0% to 0.2%) 0% (0 to 0.7%) 0.9515 
   Fibrobacteraceae 0% (0% to 0.2%) 0% (0 to 0.7%) 1.0000 
Bacteria.Firmicutes  40.4% (5.8 to 69.2%) 23.3% (4.4 to 95.2%) 0.9515 
 Bacilli  4.8% (0.5 to 32.2%) 2.4% (0.1 to 78.8%)  0.2254 
       Lactobacillales 4.8% (0.5 to 32.2%) 2.2% (0.1 to 69.8%) 0.6264 
   Aerococcaceae 0% (0 to 1.6%) 0% (0 to 1.1%) 1.0000 
   Carnobacteriaceae 0% (0 to 0.2%) 0% (0 to 0.1%) 1.0000 
   Enterococcaceae 1.2% (0 to 14.5%) 0% (0 to 65.0%) 0.0080 
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 Table Q-1 continued    
   
Lactobacillaceae 0% (0 to 7.9%) 0% (0 to 5.6%) 0.0281 
   Leuconostocaceae 0% (0 to 0.2%) 0% (0%) 1.0000 
   Streptococcaceae 2.1% (0 to 31.2%) 1.6% (0 to 20.8%) 1.0000 
     Other 0.2% (0 to 1.7%) 0% (0 to 3.8%) 0.0234 
      Bacillales 0% (0 to 0.3%) 0% (0 to 0.8%) 0.9515 
   Paenibacillaceae 0% (0 to 0.2%) 0% (0 to 0.2%) 1.0000 
   Staphylococcaceae 0% (0 to 2.5%) 0.1% (0 to 8.2%) 1.0000 
   Bacillaceae 0% (0 to 0.3%) 0% (0 to 0.1%) 1.0000 
   Incertae Sedis XI 0% (0 to 0.2%) 0% (0 to 0.1%) 1.0000 
   Planococcaceae 0% (0%) 0% (0 to 0.2%) 1.0000 
   Other 0% (0 to 0.2%) 0% (0 to 0.2%) 1.0000 
       Other order 0% (0 to 0.1%) 0% (0 to 0.5%) 0.9515 
   Other family 0% (0 to 0.1%) 0% (0 to 0.5%) 1.0000 
 Clostridia  30.1% (3.4 to 64.5%) 18.8% (3.6 to 82.5%) 0.1314 
  Clostridiales 30.1% (3.4 to 64.5%) 29.5% (3.4 to 64.5%) 0.9515 
   Eubacteriaceae 0% (0 to 2.2%) 0% (0 to 1.2%) 0.3839 
   Lachnospiraceae 3.7% (0 to 55.5%) 5.6% (0.7 to 76.7%) 1.0000 
   Peptostreptococcaceae 3.4% (0 to 20.1%) 0% (0 to 12.4%) <0.0001 
   Ruminococcaceae 0.2% (0 to 4.6%) 1.5% (0.1 to 18.5%) <0.0001 
   Clostridiaceae 7.1% (0.1 to 45.2%) 5.4% (0 to 19.0%) 0.0080 
   Incertae Sedis XI 0% (0 to 1.1%) 1.2% (0 to 14.0%) <0.0001 
   Incertae Sedis XIII 0% (0 to 0.8%) 0.1% (0 to 5.8%) 0.0080 
   Peptococcaceae 0% (0%) 0% (0 to 2.5%) 0.0438 
   Veillonellaceae 0% (0 to 8.3%) 0.9% (0 to 3.5%) <0.0001 
   Other 3.1% (0.1 to 13.7%) 2.0% (0 to 16.5%) 1.0000 
       Other order 0% (0 to 0.4%) 0.2% (0 to 23.5%) 0.0190 
   Other family 0% (0 to 0.4%) 0.2% (0 to 23.5%) 0.0375 
 Erysipelotrichi 0.1% (0 to 1.0%) 0.1% (0 to 2%) 0.5376 
        Erysipelotrichales 0.1% (0 to 1.0%) 0.1% (0 to 2%) 0.4844 
   Erysipelotrichiaceae 0.1% (0 to 1.0%) 0.1% (0 to 2%) 1.0000 
 Other class 0% (0 to 0.5%) 0.3% (0 to 6.5%) <0.0001 
    Other order 0% (0 to 0.5%) 0.3% (0 to 6.5%) <0.0001 
   Other family 0% (0 to 0.5%) 0.3% (0 to 6.5%) <0.0001 
Bacteria.Fusobacteria 0.8% (0 to 45.5%) 0.8% (0 to 42.5%) 0.9510 
 Fusobacteria 0.8% (0 to 45.5%) 0.8% (0 to 42.2%) 1.0000 
  Fusobacteriales 0.8% (0 to 45.5%) 0.8% (0 to 42.2%) 1.0000 
   Fusobacteriaceae 0.4% (0 to 45.3%) 0.8% (0 to 42.2%) 1.0000 
   Incertae sedis 11 0% (0 to 0.2%) 0% (0%) 1.0000 
   Other 0% (0 to 16.1%) 0% (0 to 1.0%) 1.0000 
Bacteria.Lentisphaerae  0% (0%) 0% (0%) NP 
 Lentisphaerae  0% (0%) 0% (0%) NP 
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 Table Q-1 continued    
  
Victivallales 0% (0%) 0% (0%) NP 
   Victivallaceae 0% (0%) 0% (0%) NP 
Bacteria. Other   0.2% (0 to 8.1%) 4.6% (0.2 to 68.5%) <0.0001 
 Bacteria. Other Class  0.2% (0 to 8.1%) 4.6% (0.2 to 68.5%) <0.0001 
  Other Order 0.2% (0 to 8.1%) 4.6% (0.2 to 68.5%) <0.0001 
   Other family 0.2% (0 to 8.1%) 4.6% (0.2 to 68.5%) <0.0001 
Bacteria.Planctomycetes  0% (0 to 0.1%) 0% (0 to 1.4%) 0.0015 
 Planctomycetacia 0% (0 to 0.1%) 0% (0 to 1.4%) 0.0322 
  Planctomycetales 0% (0 to 0.1%) 0% (0 to 1.4%) 0.0047 
   Planctomycetaceae 0% (0 to 0.1%) 0% (0 to 1.4%) 0.0080 
Bacteria.Proteobacteria  36.3% (0.5 to 85.8%) 2.7% (0 to 40.9%) <0.0001 
 Alphaproteobacteria 0% (0 to 0.3%) 0% (0 to 0.3%) 0.8167 
  Caulobacterales 0% (0 to 0.2%) 0% (0) 0.9515 
   Caulobacteriaceae 0% (0 to 0.2%) 0% (0) 1.0000 
  Rhizobiales 0% (0 to 0.2%) 0% (0 to 0.2%) 0.9515 
   Hyphomicrobiaceae 0% (0%) 0% (0 to 0.1%) 1.0000 
   Methylobacteriaceae 0% (0 to 0.1%) 0% (0 to 0.1%) 1.0000 
   Other 0% (0 to 0.2%) 0% (0 to 0.3%) 1.0000 
  Rhodobacteriales 0% (0 to 0.2%) 0% (0 to 0.1%) 0.9515 
   Rhodobacteriaceae 0% (0 to 0.2%) 0% (0 to 0.1%) 1.0000 
  Rhodospirales 0% (0%) 0% (0%) NP 
   Other  0% (0%) 0% (0%) NP 
  Other order 0% (0%) 0% (0 to 0.1%) 0.9515 
   Other family 0% (0%) 0% (0 to 0.1%) 1.0000 
 Betaproteobacteria 0% (0 to 0.2%) 0% (0 to 0.5%) 0.4698 
  Burkholderiales 0% (0 to 0.2%) 0% (0 to 0.5%) 0.9230 
   Alcaligenaceae 0% (0 to 0.1%) 0% (0 to 0.1%) 1.0000 
   Comamonadacea 0% (0 to 0.1%) 0% (0 to 0.1%) 1.0000 
   Other 0% (0 to 0.1%) 0% (0 to 0.5%) 1.0000 
  Other order 0% (0 to 0.1%) 0% (0 to 0.1%) 0.9515 
   Other family 0% (0 to 0.1%) 0% (0 to 0.1%) 1.0000 
 Deltaproteobacteria 0% (0 to 0.4%) 0% (0 to 1.1%) 0.0084 
  Desulfovibrionales 0% (0 to 0.4%) 0% (0 to 0.5%) 0.0385 
   Desulfovibrionaceae 0% (0 to 0.4%) 0% (0 to 0.5%) 0.1136 
   Other 0% (0 to 0.1%) 0% (0 to 0.2%) 1.0000 
  Myxococcales 0% (0%) 0% (0 to 1.1%) 0.9515 
   Nannocystineae 0% (0%) 0% (0 to 1.0%) 1.0000 
   Other 0% (0%) 0% (0 to 0.1%) 1.0000 
 Epsilonproteobacteria 0% (0 to 0.1%) 0.3% (0 to 16.4%) <0.0001 
  Campylobacterales 0% (0 to 0.1%) 0.3% (0 to 16.4%) <0.0001 
   Campylobacteriaceae 0% (0 to 0.1%) 0.2% (0 to 4.7%) <0.0001 
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 Table Q-1 continued    
   
  Helicobacteraceae 0% (%) 0% (0 to 15.9%) 0.0080 
 Gamma proteobacteria 36.3% (0 to 85.8%) 0.5% (0 to 40.9%) <0.0001 
  Aeromonadales 0% (0 to 3.2%) 0% (0 to 4.2%) 0.9515 
   Aeromonadaceae 0% (0 to 3.2%) 0% (0%) 0.3234 
   Succinivibrionaceae 0% (0%) 0% (0 to 4.2%) 0.0080 
  Enterobacteriales 36.2% (0 to 85.8%) 0.1% (0 to 39.8%) <0.0001 
   Enterobacteriaceae 36.2% (0 to 85.8%) 0.1% (0 to 39.8%) <0.0001 
  Legionellales 0% (0%) 0% (0 to 0.2%) 0.9515 
   Coxiellaceae 0% (0%) 0% (0 to 0.1%) 1.0000 
   Legionellaceae 0% (0%) 0% (0 to 0.2%) 1.0000 
  Oceanospirillales  0% (0 to 0.1%) 0% (0%) 0.9515 
   Halomonadaceae 0% (0 to 0.1%) 0% (0%) 1.0000 
  Pasteurellales 0% (0 to 3.6%) 0% (0 to 1.2%) 0.9515 
   Pasteurellaceae 0% (0 to 3.6%) 0% (0 to 1.2%) 1.0000 
  Pseudomonadales 0% (0 to 1.5%) 0% (0 to 1.1%) 0.9515 
   Moraxellaceae 0% (0 to 0.3%) 0% (0 to 0.7%) 1.0000 
   Pseudomonadaceae 0% (0 to 1.2%) 0% (0 to 0.4%) 1.0000 
  Xanthomonadales 0% (0%) 0% (0 to 0.1%) 0.9515 
   Xanthomonadaceae 0% (0%) 0% (0 to 0.1%) 1.0000 
  Other order 0% (0 to 0.5%) 0% (0%) 0.3278 
   Other family 0% (0 to 0.5%) 0% (0%) 1.0000 
 Other class 0% (0 to 0.2%) 0% (0 to 23.7%) 0.0099 
  Other order 0% (0 to 0.2%) 0% (0 to 23.7%) 0.0333 
   Other family 0% (0 to 0.2%) 0% (0 to 23.7%) 0.9089 
Bacteria.Spirochaetes  0% (0%) 0% (0 to 2.1%) 0.0100 
 Spirochaetes  0% (0%) 0% (0 to 2.1%) 0.0375 
  Spirochaetales 0% (0%) 0% (0 to 2.1%) 0.0360 
   Spirochaetaceae 0% (0%) 0% (0 to 2.1%) 0.0720 
   Other 0% (0%) 0% (0 to 0.2%) 1.0000 
Bacteria.TM7   0% (0%) 0% (0 to 1.8%) 0.0048 
 TM7 genera incertae sedis 0% (0%) 0% (0 to 1.8%) 0.0280 
  Other order 0% (0%) 0% (0 to 1.8%) 0.0156 
   Other family 0% (0%) 0% (0 to 1.8%) 0.0308 
Bacteria.Tenericutes  0% (0%) 0% (0 to 0.1%) 0.9515 
 Mollicutes  0% (0%) 0% (0 to 0.1%) 1.0000 
  Anaeroplasmatales 0% (0%) 0% (0 to 0.1%) 1.0000 
   Anaeroplasmataceae 0% (0%) 0% (0 to 0.1%) 1.0000 
Bacteria.Verrucomicrobia   0% (0 to 42.5%) 1.0% (0.4 to 48.7%) 0.0015 
  Verrucomicrobiae 0% (0 to 42.5%) 1.0% (0.4 to 48.7%) 0.0322 
 Verrucomicrobiales 0% (0 to 42.5%) 1.0% (0.4 to 48.7%) 0.0040 
  Other 0% (0%) 0% (0 to 0.2%) 1.0000 
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 Table Q-1 continued    
  
Subdivision 5 0% (0 to 0.2%) 0.3% (0 to 25.4%) 0.0000 
  Verrucomicrobiaceae 0% (0 to 42.5%) 0.6% (0 to 48.6%) 0.0158 
  Xiphinematobacteriaceae 0% (0%) 0% (0 to 0.2%) 1.0000 
Other Kingdom, Other phylum 0% (0 to 1.1%) 0% (0 to 0.3%) 0.9515 
 Other class 0% (0 to 1.1%) 0% (0 to 0.3%) 1.0000 
  Other order 0% (0 to 1.1%) 0% (0 to 0.3%) 1.0000 
   Other family 0% (0 to 1.1%) 0% (0 to 0.3%) 1.0000 
 
Fecal swab samples were collected from 37 Quarter Horse foals on days 2 and 30 of life 
*P values represent the results of Wilcoxon sign-rank tests for paired differences, 
adjusted by the method of Hochberg.  
NP = Not Performed 
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APPENDIX R 
 
Table R-1 
Median and range proportion of foals with sequences detected in the fecal DNA of rectal 
swab samples (Phylum, class, order, and family).  
 
 
 
Microbial Family 2-day-old foals 
(N=37) 
30-day-old foals (N = 37) P* 
Archaea.Euryarchaeota  0% (0/37) 35% (13/37) 0.0117 
 Methanobacteria 0% (0/37) 24% (9/37) 0.0770 
       Methanobacteriales 0% (0/37) 24% (9/37) 0.1925 
   Methanobacteriacae 0% (0/37) 24% (9/37) 0.4851 
 Methanomicrobia 0% (0/37) 16% (6/37) 0.3708 
       Methanomicrobiales 0% (0/37) 16% (6/37) 0.9064 
   Methanocorpusculaceae 0% (0/37) 16% (6/37) 1.0000 
Bacteria.Acidobacteria  0% (0/37)   3% (1/37) 0.9999 
 Acidobacteria 0% (0/37)   3% (1/37) 1.0000 
  Acidobacteriales 0% (0/37)   3% (1/37) 1.0000 
   Acidobacteriaceae 0% (0/37)   3% (1/37) 1.0000 
Bacteria.Actinobacteria  73% (27/37) 97% (36/37) 0.1590 
 Actinobacteria 73% (27/37) 97% (36/37) 0.1925 
  Actinomycetales (order) 62% (23/37) 73% (27/37) 1.0000 
  Bifidobacteriales (order) 3% (1/37) 8% (3/37) 1.0000 
  Other 14% (5/37) 8% (3/37) 1.0000 
 Coriobacteridae (subclass) 24% (9/37) 76% (28/37) 0.0041 
  Coriobacteriales 24% (9/37) 76% (28/37) 0.0221 
 Rubrobacteridae (subclass) 3% (1/37) 0% (0/37) 1.0000 
  Rubrobacterales 3% (1/37) 0% (0/37) 1.0000 
  Other order 0% (0/37) 27% (10/37) 0.1452 
   Other family 0% (0/37) 27% (10/37) 0.2944 
Bacteria.Bacteroidetes  92% (34/37) 100% (37/37) 0.5152 
 Bacteroidetes 89% (33/37) 100% (37/37) 1.0000 
      Bacteroidales 89% (33/37) 100% (37/37) 1.0000 
   Bacteroidieacae 86% (32/37) 95% (35/37) 1.0000 
   Porphyromonadaceae 30% (11/37) 89% (33/37) <0.0001 
    Prevotellaceae 8% (3/37) 95% (35/37) <0.0001 
   Rikenellaceae 11% (4/37) 49% (18/37) 0.1496 
   Other 11% (4/37) 95% (35/37) <0.0001 
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Flavobacteria  16% (6/37) 11% (4/37) 1.0000 
     Flavobacteriales 16% (6/37) 11% (4/37) 1.0000 
   Flavobacteriaceae 16% (6/37) 11% (4/37) 1.0000 
 Sphingobacteria 5% (2/37) 3% (1/37) 1.0000 
       Sphingobacteriales 5% (2/37) 3% (1/37) 1.0000 
     Crenotrichaceae 3% (1/37) 0% (0/37) 1.0000 
   Flexibacteriaceae 0% (0/37) 3% (1/37) 1.0000 
   Sphingobacteriaceae 3% (1/37) 0% (0/37) 1.0000 
 Other class 27% (10/37) 95% (35/37) <0.0001 
  Other order 27% (10/37) 95% (35/37) <0.0001 
   Other family 27% (10/37) 95% (35/37) <0.0001 
Bacteria.Chlamydiae  0% (0/37) 51% (19/37) <0.0001 
   Chlamydiae 0% (0/37) 51% (19/37) <0.0001 
  Chlamydiales 0% (0%) 51% (19/37) <0.0001 
   Chlamydiaceae 0% (0%) 51% (19/37) <0.0001 
   Parachlamydiaceae 0% (0%) 3% (1/37) 1.0000 
Bacteria.Chloroflexi  0% (0/37) 22% (8/37) 0.1463 
 Anaerolineae 0% (0/37) 22% (8/37) 0.1173 
 Caldilineae  0% (0/37) 3% (1/37) 1.0000 
  Caldilineales 0% (0/37) 3% (1/37) 1.0000 
  Other  0% (0/37) 19% (7/37) 0.7223 
   Other family 0% (0/37) 19% (7/37) 1.0000 
Bacteria.Cyanobacteria  0% (0/37)   3% (1/37) 0.9999 
 Cyanobacteria 0% (0/37)   3% (1/37) 1.0000 
  Other order 0% (0/37)   3% (1/37) 1.0000 
   Other family 0% (0/37) 3% (1/37) 1.0000 
Bacteria.Deferribacteres  3% (1/37)   5% (2/37) 0.9999 
 Deferribacteres 3% (1/37)   5% (2/37) 1.0000 
  Deferribacterales 3% (1/37)   5% (2/37) 1.0000 
   Deferribacteraceae 0% (0%) 0% (0%) NP 
   Incertae sedis 3 3% (1/37) 5% (2/37) 1.0000 
Bacteria.Fibrobacteres  0% (0/37) 14% (5/37) 0.5152 
 Fibrobacteres 0% (0/37) 14% (5/37) 0.4698 
  Fibrobacterales 0% (0/37) 14% (5/37) 0.9515 
   Fibrobacteraceae 0% (0/37) 14% (5/37) 1.0000 
Bacteria.Firmicutes  100% (37/37) 100% (37/37) NP 
 Bacilli  100% (37/37) 100% (37/37)  NP 
       Lactobacillales 100% (37/37) 100% (37/37)  NP 
   Aerococcaceae 27% (10/37) 14% (5/37) 1.0000 
   Carnobacteriaceae 14% (5/37) 3% (1/37) 1.0000 
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Enterococcaceae 95% (35/37) 41% (15/37) 0.0078 
   Lactobacillaceae 27% (10/37) 70% (26/37) 0.2944 
   Leuconostocaceae 8% (3/37) 0% (0/37) 1.0000 
   Streptococcaceae 97% (36/37) 97%(36/37) 1.0000 
     Other 78% (29/37) 22% (8/37) <0.0001 
      Bacillales 46% (17/37) 70% (26/37) 1.0000 
   Paenibacillaceae 3% (1/37) 5% (2/37) 1.0000 
   Staphylococcaceae 32% (12/37) 62% (23/37) 1.0000 
   Bacillaceae 14% (5/37) 14% (5/37) 1.0000 
   Incertae Sedis XI 11% (4/37) 3% (1/37) 1.0000 
   Planococcaceae 3% (1/37) 11% (4/37) 1.0000 
   Other 0% (0/37) 8% (3/37) 1.0000 
       Other order 30% (11/37) 11% (4/37) 1.0000 
   Other family 30% (11/37) 11% (4/37) 1.0000 
 Clostridia  100% (37/37) 100% (37/37)  NP 
  Clostridiales 100% (37/37) 100% (37/37) NP 
   Eubacteriaceae 5% (2/37) 35% (13/37) 0.6076 
   Lachnospiraceae 89% (33/37) 100% (37/37) 1.0000 
   Peptostreptococcaceae  43% (16/37) 0.0150 
   Ruminococcaceae 70% (26/37) 100% (37/37) 0.1716 
   Clostridiaceae 100% (37/37) 78% (29/37) 0.7980 
   Incertae Sedis XI 11% (4/37) 78% (29/37) <0.0001 
   Incertae Sedis XIII 5% (2/37) 57% (21/37) 0.0154 
   Peptococcaceae 0% (0/37) 32% (12/37) 0.1065 
   Veillonellaceae 16% (6/37) 95% (35/37) <0.0001 
   Other 100% (37/37) 97% (36/37) 1.0000 
       Other order 32% (12/37) 59% (22/37) 0.8136 
   Other family 32% (12/37) 59% (22/37) 1.0000 
 Erysipelotrichi   62% (23/37)   70% (26/37) 1.0000 
        Erysipelotrichales  62% (23/37)   70% (26/37) 1.0000 
   Erysipelotrichiaceae   62% (23/37)   70% (26/37) 1.0000 
 Other class   49% (18/37)   86% (32/37) 0.0242 
    Other order   49% (18/37)   86% (32/37) 0.0594 
   Other family   49% (18/37)   86% (32/37) 1.0000 
Bacteria.Fusobacteria 62% (23/37) 84% (31/37) 0.5152 
 Fusobacteria 62% (23/37) 84% (31/37) 1.0000 
  Fusobacteriales 62% (23/37) 84% (31/37) 1.0000 
   Fusobacteriaceae 62% (23/37) 81% (30/37) 1.0000 
   Incertae sedis 11  5% (2/37) 0% (0/37) 1.0000 
   Other 32% (12/37) 43% (16/37) 1.0000 
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Bacteria.Lentisphaerae  0% (0/37) 0% (0/37) NP 
 Lentisphaerae  0% (0/37) 0% (0/37) NP 
  Victivallales 0% (0/37) 0% (0/37) NP 
   Victivallaceae 0% (0/37) 0% (0/37) NP 
Bacteria.Other   86% (32/37) 100% (37/37) 0.5152 
 Bacteria. Other Class  86% (32/37) 100% (37/37) 1.0000 
  Other Order 86% (32/37) 100% (37/37) 1.0000 
   Other family 86% (32/37) 100% (37/37) 1.0000 
Bacteria.Planctomycetes  3% (1/37) 43% (16/37) 0.0045 
 Planctomycetacia 3% (1/37%) 43% (16/37) 0.0377 
  Planctomycetales 3% (1/37) 43% (16/37) 0.0120 
   Planctomycetaceae 3% (1/37) 43% (16/37) 0.0003 
Bacteria.Proteobacteria  100% (37/37) 97% (36/37) 0.9999 
 Alphaproteobacteria 11% (4/37) 14% (5/37) 1.0000 
  Caulobacterales 3% (1/37) 0% (0/37) 1.0000 
   Caulobacteriaceae 3% (1/37) 0% (0/37) 1.0000 
  Rhizobiales 5% (2/37) 8% (3/37) 1.0000 
   Hyphomicrobiaceae 0% (0/37) 3% (1/37) 1.0000 
   Methylobacteriaceae 3% (1/37) 3% (1/37) 1.0000 
   Other 3% (1/37) 3% (1/37) 1.0000 
  Rhodobacteriales 5% (2/37) 3% (1/37) 1.0000 
   Rhodobacteriaceae 5% (2/37) 3% (1/37) 1.0000 
  Rhodospirales 0% (0%) 0% (0%) NP 
   Other  0% (0%) 0% (0%) NP 
  Other order 0% (0%) 3% (1/37) 1.0000 
   Other family 0% (0%) 3% (1/37) 1.0000 
 Betaproteobacteria 11% (4/37) 27% (10/37) 1.0000 
  Burkholderiales 8% (3/37) 24% (9/37%) 1.0000 
   Alcaligenaceae 3% (1/37) 3% (1/37) 1.0000 
   Comamonadacea 3% (1/37) 8% (3/37) 1.0000 
   Other 3% (1/37) 14% (5/37) 1.0000 
  Other order 5% (2/37) 3% (1/37) 1.0000 
   Other family 5% (2/37) 3% (1/37) 1.0000 
 Deltaproteobacteria   5% (2/37) 49% (18/37) 0.0104 
  Desulfovibrionales   5% (2/37) 46% (17/37) 0.0377 
   Desulfovibrionaceae   5% (2/37) 43% (16/37) 0.1496 
   Other   3% (1/37) 14% (5/37) 1.0000 
  Myxococcales   0% (0/37) 3% (1/37) 1.0000 
   Nannocystineae 0% (0/37) 3% (1/37) 1.0000 
   Other 0% (0/37) 0% (0/37) NP 
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Epsilonproteobacteria  3% (1/37) 73% (27/37) <0.0001 
  Campylobacterales  3% (1/37) 73% (27/37) <0.0001 
   Campylobacteriaceae 3% (1/37) 65% (24/37) <0.0001 
     Helicobacteraceae 0% (0/37) 43% (16/37) 0.0154 
 Gamma proteobacteria 97% (36/37) 89% (33/37) 1.0000 
  Aeromonadales 22% (8/37) 41% (15/37) 1.0000 
   Aeromonadaceae 22% (8/37) 0% (0/37) 0.7980 
   Succinivibrionaceae 0% (0/37) 41% (15/37) 0.0219 
  Enterobacteriales 95% (35/37) 62% (23/37) 0.0858 
   Enterobacteriaceae 95% (35/37) 62% (23/37) 0.2145 
  Legionellales 0% (0/37) 5% (2/37) 1.0000 
   Coxiellaceae 0% (0/37) 3% (1/37) 1.0000 
   Legionellaceae 0% (0/37) 3% (1/37) 1.0000 
  Oceanospirillales  3% (1/37) 0% (0/37) 1.0000 
   Halomonadaceae 3% (1/37) 0% (0/37) 1.0000 
  Pasteurellales 32% (12/37) 38% (14/37) 1.0000 
   Pasteurellaceae 32% (12/37) 38% (14/37) 1.0000 
  Pseudomonadales 14% (5/37) 11% (4/37) 1.0000 
   Moraxellaceae 14% (5/37) 11% (4/37) 1.0000 
   Pseudomonadaceae 5% (2/37) 3% (1/37) 1.0000 
  Xanthomonadales 0% (0/37) 3% (1/37) 1.0000 
   Xanthomonadaceae 0% (0/37) 3% (1/37) 1.0000 
  Other order 16% (6/37) 0% (0/37) 0.9064 
   Other family 16% (6/37) 0% (0/37) 1.0000 
 Other class 5% (2/37) 43% (16/37) 0.0242 
  Other order 5% (2/37) 43% (16/37) 0.0594 
   Other family  5% (2/37) 43% (16/37) 0.1496 
Bacteria.Spirochaetes  0% (0/37) 30% (11/37) 0.0312 
 Spirochaetes  0% (0/37) 30% (11/37) 0.0439 
  Spirochaetales 0% (0/37) 30% (11/37) 0.0910 
   Spirochaetaceae 0% (0/37) 30% (11/37) 0.1716 
   Other 0% (0/37) 3% (1/37) 1.0000 
Bacteria.TM7   0% (0/37) 35% (13/37) 0.0117 
 TM7 genera incertae sedis 0% (0/37) 35% (13/37) 0.0218 
  Other order 0% (0/37) 35% (13/37) 0.0351 
   Other family 0% (0/37) 35% (13/37) 0.0648 
Bacteria.Tenericutes  0% (0/37) 3% (1/37) 1.0000 
 Mollicutes  0% (0/37) 3% (1/37) 1.0000 
  Anaeroplasmatales 0% (0/37) 3% (1/37) 1.0000 
   Anaeroplasmataceae 0% (0/37) 3% (1/37) 1.0000 
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Bacteria.Verrucomicrobia   24% (9/37) 89% (33/37) <0.0001 
  Verrucomicrobiae 24% (9/37) 89% (33/37) <0.0001 
 Verrucomicrobiales 24% (9/37) 89% (33/37) <0.0001 
  Other 0% (0%) 5% (2/37) 1.0000 
  Subdivision 5 8% (3/37) 76% (28/37) <0.0001 
  Verrucomicrobiaceae 16% (6/37) 78% (29/37) <0.0001 
  Xiphinematobacteriaceae 0% (0%) 3% (1/37) 1.0000 
Other Kingdom, Other phylum 19% (7/37) 22% (8/37) 0.9999 
 Other class 19% (7/37) 22% (8/37) 1.0000 
  Other order 19% (7/37) 22% (8/37) 1.0000 
   Other family 19% (7/37) 22% (8/37) 1.0000 
 
Fecal swab samples collected from 37 Quarter Horse foals on days 2 and 30 of life 
*P values represent the results of McNemar’s test for paired dichotomous data, adjusted 
by the method of Hochberg 
NP = Not Performed  
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APPENDIX S 
 
 
 
The following paper was initially prepared to be sent publication as one single 
paper, but the main results were added to Chapter II, therefore, this paper was added as 
an appendix to all results and discussion can be used as future reference.  
Selection of electron-beam irradiation dose for inactivation of Rhodococcus equi 
 
Overview 
 
Rhodococcus equi is a bacterium commonly isolated from soil that primarily 
causes pneumonia in foals. The objectives of our study were to evaluate electron-beam 
(e-beam) irradiation as a method of inactivation of R. equi and to establish an e-beam 
dose that inactivated all microorganisms without disrupting cellular integrity. Two 
concentrations of R. equi  (Concentration 1, approximately 1 × 108 colony-forming 
units/ml [CFU/ml] and concentration 2, approximately 1 × 109 CFU/ml) were irradiated 
with e-beam doses ranging from 0 to 7 kGy and quantitatively cultured for calculation of 
the D10-value. Live and heat-inactivated R. equi were used as positive and negative 
controls, respectively. Samples irradiated with selected doses that achieved complete 
inactivation were evaluated by transmission electron microscopy (TEM) and 
fluorescence-based viability at 12 hours and 1, 2, and 4 weeks after irradiation.   All 
microorganisms for concentrations 1 and 2 were adequately inactivated at 4 kGy and 5 
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kGy, respectively, and the D10-value of R. equi was estimated to be 0.505 kGy. 
Ultrastructurally, the overall integrity of the outer bacterial cell wall of all treated groups 
was preserved.  Changes affecting the wall were confined to the layered cell wall of all 
groups, and were more severe among bacteria of heat-inactivated groups suggesting a 
more severe compromise of the cell wall integrity.  Fluorescence data were similar for 
concentrations 1 and 2, as well as for live bacteria, indicating an intact the cell wall, 
whereas fluorescence data for heat-inactivated samples indicated a compromised cell 
wall. Results of our study suggest that e-beam radiation completely inactivated R. equi 
samples, while retaining their structural integrity. Electron-beam irradiation is an 
appropriate method of inactivation of R. equi for in vitro studies of immune responses to 
inactivated bacteria and possibly for use as a vaccine in foals against R. equi pneumonia. 
Keywords: bacteria, ionizing radiation, microbiology, vaccine, pathogen 
 
 
 
Introduction 
 
 
Rhodococcus equi is a facultative intracellular pathogen recognized clinically as 
a leading cause of severe pneumonia in foals [S-1- S-4]. Although a variety of strategies 
have been evaluated for vaccination against R. equi, including immunization of mares 
[S-5- S-9] inactivated R. equi administered parenterally to foals or mice [S-7, S-10], sub-
unit vaccines [S-8, S-9, S-11], DNA vaccines [S-12, S-13], and live, mutant vaccines [S-
14, S-15], oral administration of live, virulent R. equi is the only vaccination strategy 
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that has been demonstrated repeatedly to be effective for protecting foals against 
experimental intrabronchial challenge with virulent R. equi [S-16- S-18]. The 
administration of live, virulent organisms is not considered an acceptable strategy for 
vaccination of foals.  To date, an efficacious vaccine against R. equi for foals is lacking 
and there is no approved vaccine for foals against R. equi in North America.  
Inactivated bacteria and viruses can elicit protective immune responses against 
systemic infections, including those of the respiratory tract [S-19- S-22]. Electron-beam 
(e-beam) irradiation is a technology for microbial inactivation that is currently used for 
sterilization and pasteurization [S-23- S-26]. Electron-beam irradiation at appropriate 
doses can be used to inactivate large volumes of microbial cultures or to sterilize 
materials [S-27- S-29]. Electron-beam inactivation has advantages relative to 
inactivating bacteria using heat or formalin.  Inactivation with either heat or formalin is 
known to denature proteins, including immunogenic epitopes on the cell surface [S-30, 
S-31]. More importantly, formalin is widely recognized as resulting in incomplete 
inactivation of organisms, and has been associated with vaccine-associated disease 
resulting from inadequate inactivation [S-32]. Thus, there is need for a reliable method 
of microbial inactivation that will retain the bacterial cell structure as similar as possible 
to a live organism for use in producing vaccines. We therefore investigated the use e-
beam irradiation as a method for microbial inactivation for potential use for making 
vaccines. Our objective was 2-fold: 1) to select a dose of e-beam radiation that would 
render R. equi completely incapable of replication for 2 different concentrations of this 
bacterium; and, 2) to study the effects of the minimal dose of irradiation that provided 
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complete inactivation on the integrity of the  R. equi bacterial cell wall in both freshly 
irradiated and refrigerated samples by using transmission electron microscopy (TEM) 
and a 2-color fluorescence assay, using live (positive control), heat-inactivated (negative 
control), and electron-beam irradiated R. equi at different time-points after exposure to 
e-beam radiation. 
 
Material and methods 
 
Preparation of bacteria and electron beam irradiation   
Blood agar plates were inoculated with R. equi strain EIDL 5-331, and incubated 
at 37oC for 48 hours. One colony from this pure culture was selected and used to 
inoculate 50 ml of brain-heart infusion (BHI) broth. The flask with inoculated broth was 
placed on a shaker for 24 h at 37oC. Ten ml of this pure culture were used to inoculate 
1000 ml of BHI broth. The flask with inoculated broth was placed on a shaker for 24 h at 
37oC. The bacterial suspension was divided into 5 aliquots of 200 ml, centrifuged at 
3400 × g (Eppendorf AG, Hamburg, Germany) for 20 min at 4oC, the supernatant 
discarded, and the pellets resuspended with 100 ml of phosphate-buffered saline (PBS). 
The resuspended pellet was centrifuged again using the same centrifugation protocol. 
The supernatant was discarded, and the bacteria were resuspended in sterile 0.9% NaCl 
solution. The initial concentration of bacteria was determined spectrophotometrically 
(Genesys™ 20, Thermo Scientific, Waltham, MA, USA). Two approximate 
concentrations were used, Concentration 1, approximately 1 × 108 colony-forming units 
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(CFU), and Concentration 2, approximately 1 × 109 CFU. Twenty-five ml of each 
concentration were dispensed in a 3- x 7-inch Whirl Pak bag (Uline, Pleasant Prairie, 
WI, USA), the bag tightly heat-sealed with no headspace, placed inside another Whirl 
Pak bag, and heat-sealed for a second time. The double-bagged bacteria were then 
placed inside a 95-kPa transport bag (Therapak, Duarte, CA, USA) and sealed. A total of 
8 transport bags were placed inside a transport box (Saf-T-Pak, Glen Burnie, MD, USA) 
and transported to the National Center for Electron Beam Research at Texas A&M 
University for irradiation. Although high doses of e-beam radiation can completely 
inactivate all microorganisms, our objective was to determine the lowest dose able to 
achieve complete inactivation with least amount of damage to bacteria. Each bag was 
exposed to an irradiation dose ranging from 0 to 7 kGy (in integer-unit doses) using a 
10-MeV, 18-kW linear accelerator. Alanine dosimeters were used to verify the delivered 
e-beam dose. Twenty-five ml of non-irradiated heat-inactivated bacteria were inactivated 
for 30 min in a water bath at 85oC, and were used as the negative control. After 
irradiation, quantitative culture was performed to determine concentration of each 
irradiated sample, and to calculate the D10-value. Experiments were conducted in 
triplicates, performed on 3 different days. The D10-value was calculated from the 
negative inverse of the slope from the linear regression between the dose and the 
logarithm of the microbial population [S-33].  
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Cell wall integrity of irradiated R. equi 
Bacteria were cultured as described above, and the minimum dose that 
effectively inactivated all microorganisms for both concentrations was selected based on 
the results of quantitative culture. Eight bags of each concentration were irradiated with 
the respective selected doses, and both live and heat-inactivated R. equi were prepared as 
positive and negative controls. Samples were kept at 4oC for 12 h, and 1, 2, and 4 weeks 
after either irradiation or heat-inactivation. Two methods were used to determine 
whether the bacterial cell wall was intact.  The first method was a fluorescence-based 
assay (LIVE/DEAD® BacLight™ bacterial viability kit, Molecular Probes, Inc., 
Eugene, OR, USA), which utilizes a mixture of SYTO® 9 green-fluorescent nucleic acid 
stain and propidium iodide.  The SYTO® 9 generally stains all bacteria in a population, 
regardless of the integrity of the cell membrane. In contrast, propidium iodide penetrates 
only bacteria with damaged membranes, resulting in a reduction in the SYTO® 9 stain 
fluorescence when both dyes are present [S-34]. Preparations of live, heat-inactivated, 
and e-beam irradiated R. equi were evaluated at 12 h, and 1, 2, and 4 weeks after 
processing according to manufacturer’s instructions using a microplate reader (Synergy 
2, Biotek, Winooski, VT, USA). We expected to observe that irradiation did not increase 
propidium iodide staining, indicating that the cell walls of the bacteria remained intact, 
but replication-incompetent. 
In the second experiment, the integrity of the bacterial cell wall of irradiated 
samples, heat-inactivated, and live R. equi was evaluated using TEM within 12 h, and 1, 
2, or 4 weeks after processing. Bacterial cells were fixed in 2% glutaraldehyde, 3% 
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formaldehyde in 0.1 M sodium cacodylate buffer, then post-fixed with 1% osmium 
tetroxide and 0.5% potassium ferrocyanide, dehydrated in an ascending alcohol series, 
and embedded in epoxy resin. Ultrathin sections of the cells were examined with an FEI 
Morgagni 268 transmission electron microscope at an accelerating voltage of 80 kV. 
Digital images were acquired with a MegaView III camera operated with iTEM software 
(Olympus Soft Imaging Systems, Germany), then post-processed with Adobe 
Photoshop. We expected to see that e-beam radiation did not alter cell membranes and 
that only the nucleoid region would appear different between irradiated and live bacteria. 
 
Data analysis  
Data from the quantitative culture (and D10-value calculation) were analyzed 
using a linear mixed-effects model fit by REML. Analyses were conducted using S-
PLUS (Version 8.0; Insightful, Inc.) and R (Version 2.12.1; R Statistical Project). The 
cell wall integrity data (LIVE/DEAD® BacLight™ bacterial viability kit and TEM) 
were descriptive only. 
 
Results 
 
Inactivation of R. equi by electron-beam irradiation 
Samples from both concentrations of R. equi were e-beam irradiated with a dose 
ranging from 0 to 7 kGy (Fig. S-1A and B). After e-beam irradiation, quantitative culture 
was performed on all samples (Table S-1, Fig. S-2A and B). For concentration 1, e-beam 
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irradiation with 4 kGy inactivated all microorganisms (Fig. S-2A), and for concentration 
2, the dose needed to inactivate all microorganisms was 5 kGy (Fig. S-2B). Therefore, 
the doses selected for the membrane integrity studies for concentrations 1 and 2 were, 
respectively, 4 and 5 kGy. 
The D10-value was calculated from the negative inverse of the slope from the 
linear mixed-effects regression of the irradiation dose on the logarithm of the microbial 
population [33] The D10-values estimated for Rhodococcus equi strain 5-331 in 0.9% 
NaCl exposed to 10-MeV, 18-kW e-beam irradiation for the 2 concentrations were 
similar (approximately 0.505 kGy; Table S-2) and did not differ significantly (P>0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S-1. Dose-range of electron-beam irradiated Rhodococcus equi concentration 1 (A) and 2 (B). Each 
column for each dose-range represents the actual dose used in each of 3 experiments (1 experiment = 1 
study-day). (Light gray: experiment 1, Dark gray: experiment 2, Black: experiment 3). 
 
 
 
A 
 
B 
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Fig. S-2. Survival curves for R. equi samples resuspended in 0.9% NaCl treated with 0 to 7 kGy of e-beam 
irradiation. Each individual curve represents 1 experiment performed on separate days. Panel A) 
Concentration 1; Panel B) Concentration 2. Circle: Experiment 1, Triangle: Experiment 2, Square: 
Experiment 3 
 
 
 
 
 
Table S-1 
Colony-forming units per ml (CFU/ml) of 2 concentrations of Rhodococcus equi culture after inactivation 
with different doses (kGy) of e-beam irradiation on 3 different days 
 
e-beam 
irradiation 
dose (kGy) 
Experiments concentration 1 (CFU/ml)  Experiments concentration 2 (CFU/ml) 
1 2 3  1 2 3 
0 1.43 × 108 1.06 × 108 1.07 × 108  1.13 × 109 8.70 × 108 8.90 × 108 
1 7.50 × 104 5.60 × 104 1.30 × 104  7.10× 107 2.80 × 107 9.50 × 106 
2 3.00 × 102 1.01 × 103 2.05 × 103  1.40 × 106 3.00 × 105 6.60 × 104 
3 2.00 × 101 3.00 × 101 1.05 × 102  1.77 × 104 3.60 × 103 1.20 × 103 
4 0 0 0  4.05 × 102 7.00 × 101 0 
5 0 0 0  0 0 0 
6 0 0 0  0 0 0 
7 0 0 0  0 0 0 
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Table S-2  
Mean (95% confidence intervals) D10-values of concentrations 1 and 2 of Rhodococcus equi culture after 
inactivation with e-beam radiation. 
 
Concentration of R. equi 
(CFU/ml)  D10-value (kGy) for R. equi in 0.9% NaCl* 
1 (approximately 1 × 108)   0.48 (0.37 to 0.69) 
2 (approximately 1 × 109)  0.53 (0.47 to 0.61) 
 
 
 
 
 
Cell wall integrity of R. equi following electron-beam irradiation 
The cell integrity was evaluated by 2 methods in the first 24 hours, 1, 2 and 4 
weeks after e-beam irradiation. The first method used was the fluorescence-based assay 
LIVE/DEAD® BacLight™ bacterial viability kit. In all samples, the green/red 
fluorescence ratio increased with the addition of intact bacteria in all groups with the 
exception of the heat-inactivated bacteria (Fig. S-3A, B, C and D), indicating that heat-
inactivated bacteria had damaged membranes. 
The second method of cell integrity evaluation was TEM. Ultrastructurally, the 
overall integrity of the outer bacterial cell wall of all treated groups was preserved (Fig. 
S-4A, B, C, and D).  Changes affecting the wall were confined to the layered cell wall 
(LCW) of all groups, and were more severe among bacteria of heat-inactivated groups 
suggesting a more severe compromise of the cell wall integrity (consistent with the 
fluorescent-based cell wall integrity assay).  The internal cell contents were only 
morphologically affected in bacteria of the heat-inactivated group.  Noticeable changes 
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included enlarged nuclear areas that were admixed with a filamentous material and 
inconspicuous glycogen-like deposits (Fig. S-4B).  
 
 
 
 
Fig. S-3. Ratio of green/red fluorescence using the fluorescence-based LIVE/DEAD BacLight bacterial 
viability kit for Concentration 1 (approximately 1 × 108 colony-forming CFU/ml; square) and 
Concentration 2 (approximately 1 × 109 CFU/ml; triangle) e-beam irradiated, live (diamond shape) and 
heat-inactivated samples (circle). A) Day 1, B) Week 1, C) Week 2, and D) Week 4 of storage at 4oC. 
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Fig. S-4. Ultrastructure of live, heat-inactivated, and e-beam irradiated R. equi. a) Live group, week 4. 
Normal morphologic appearance of the nuclear area (NA). b) Live group, day 1. Closer magnification of a 
live bacterium depicting the localization of the layered cell wall (black arrows) and of glycogen-like 
material (white arrowheads). c) Concentration 2 e-beam irradiated, week 4. Similar morphologic 
appearance of the NA compared to the live bacterium of image “a”.  The arrows are indicating 
invaginations of the layered cell wall.  d) Concentration 1 e-beam irradiated, day 1. Closer view of 
radiated bacteria demonstrating intact layered cell walls (black arrowheads), invaginations of the layered 
wall (arrow), and preservation of glycogen-like material (white arrowheads). e) Heat-inactivated group, 
day 1. Nuclear area (NA) markedly vacuolated and has increased electron lucency. f) Heat-inactivated, 
day 1. Closer magnification of a heat-killed bacterium that presents large areas where the layered cell wall 
is either not present (arrows) or presents marked invagination/coiling (arrowheads). Note the vacuolated 
nuclear area (*), and inconspicuous glycogen-like material. 
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Discussion 
 
The objectives of this study were 2-fold: 1) to select a minimal dose of e-beam 
irradiation that would prevent replication of any R. equi present in 2 different 
concentrations of R. equi; and, 2) to study the effects of irradiation of the lowest doses 
that rendered R. equi replication-incompetent at each concentration on the integrity of 
the R. equi bacterial cell wall in both freshly irradiated and refrigerated samples.  
For the initial studies of selection of the dose to completely inhibit replication, a 
series of irradiation doses that ranged from 0 to 7 kGy, in 1-kGy increments, were used. 
The doses, as expected, did not vary among the triplicates, as portrayed in Fig. S-1A and 
1B. Bacterial survival was inversely related to e-beam irradiation dose (Fig. S-2A and 
2B), as previously reported for other microorganisms including Escherichia coli K-12 
[S-35], Bacillus atrophaeus [S-36], and avian influenza virus [S-29]. Replication of  
R. equi at both concentrations 1 and 2 was completely inhibited when irradiated with 4 
and 5 kGy, respectively (Table S-1, and Fig. S-2A and B). This difference in doses 
between concentrations was likely attributable to concentration 2 having more bacteria 
than concentration 1, requiring a higher irradiation dose to achieve complete inhibition 
of replication. Because we only evaluated integer doses of irradiation, it is possible that 
inactivation of replication could have been achieved with doses between 3 and 4 kGy 
and 4 and 5 kGy for concentrations 1 and 2, respectively; from the standpoint of safety, 
we considered erring on the side of a slightly higher dose to be desirable.  Depending on 
the bacterial growth phase, a higher dose might be needed for complete inhibition of 
  194 
bacterial replication because bacterial cells in logarithmic growth phase can have 
multiple copies of their genomes per cell [S-37].  It is also worth considering that 
bacterial cells were irradiated freshly after overnight culture, and their concentration was 
estimated based on their optical density (OD) value. Therefore, the estimated 
concentration of R. equi form the OD might be slightly different than their actual 
concentration determined after 48 hours of culture because of the effects on the OD of 
the presence of cells that died or were otherwise damaged and not replicating. 
Nevertheless, because of evidence that the more bacteria in the culture the higher the 
dose needed for complete inhibition of bacterial replication, we chose to err on the side 
of a higher dose for inactivating R. equi.  
We estimate the D10-value for R. equi to be 0.505 kGy when resuspended in 
0.9% NaCl.  The  very small difference in D10-values observed for the 2 R. equi 
concentrations studied (Table S-2) was not statistically significant and likely attributable 
to random variation in the sample and processing of material, such as different starting 
concentration of bacteria, the amount of headspace with air in the irradiation bag, 
placement of the sample in the e-beam, etc.  The initial CFU counts for the 3 replicates 
performed on separate days varied (Table S-1), and this variation was attributed to 
random day-to-day variation.  In E. coli and Salmonella typhimurium LT2 inoculated in 
fresh produce, the oxygen amount in the headspace, among other factors, affected the 
D10-value [S-38].  Thus, the small difference in observed D10 values could have been 
caused by such random variations as small differences in starting concentrations of 
bacteria or air in the headspace.  The media in which bacteria are irradiated can 
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influence their sensitivity to irradiation [S-36, S-38]. Physiologic saline (i.e., NaCl 0.9%) 
is commonly used as a diluent in medications and vaccines because of its isotonic 
characteristics. Physiological saline was used as the diluent medium in our experiments 
because this preparation of inactivated R. equi could potentially be used as a vaccine for 
foals. 
After the selection of a dose to completely inhibit replication, the LIVE/DEAD® 
BacLight™ bacterial viability kit was used to evaluate the integrity of the bacterial cell 
wall in irradiated and control samples. Fluorescence data from both dyes in each sample 
(irradiated, live, and heat-inactivated) were used to create a ratio of intact to damaged 
cells. We observed similar ratios for both concentrations of irradiated bacteria tested and 
live samples for all time-points (day 1, weeks 1, 2, and 4), whereas the heat-inactivated 
samples were considered damaged at all time-points. This finding was anticipated 
because e-beam irradiation was expected to damage the bacterial DNA [S-37], but not 
the cell wall per se. In Bacillus species spores, e-beam irradiation caused membrane 
disruption with cytoplasm leakage when high doses (i.e., ≥10.4 kGy) were used [S-39]. 
In our study, however, we did not evaluate bacterial structure in samples irradiated with 
> 5 kGy.  
We used TEM to evaluate the ultrastructure of irradiated, heat-inactivated, and 
live R. equi samples. The ultrastructure of live R. equi cells evaluated with TEM has 
been described previously [S-40].  In our study, all control and irradiated samples 
preserved the overall structural integrity of the cell wall, meaning that changes in the cell 
wall indicative of destruction or perforation of the bacterial cell wall were not observed.  
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However, morphologic changes affecting ultrastructural components of the cell wall 
(e.g., the layered cell wall) and internal structures (e.g., nuclear area and glycogen-like 
deposits) were observed.  Although variation in severity of changes involving the 
ultrastructural components of the cell wall was found between the irradiated and heat-
inactivated groups, morphologic changes in internal structures only were detected in the 
heat-inactivated bacteria. Preservation of the cell wall integrity after e-beam irradiation 
has also been shown for Paracoccidioides brasiliensis [S-39], and membrane damage of 
Bacillus spp. spores was observed only at high doses of e-beam irradiation [S-39].  
Although the evaluation of the ultrastructure in our study did not reveal changes in the 
cell wall indicative of perforation or destruction of the cell in any of the treatment 
groups, the fluorescence data from the LIVE/DEAD® BacLight™ bacterial viability kit, 
coupled with the presence of more severe ultrastructural changes affecting the layered 
cell wall of heat-inactivated bacteria, indicate that the cell wall of heat-inactivated 
bacteria were more severely compromised relative to the other treatment groups.  For 
this study, we used a heat-inactivation protocol of 85oC for 30 min.  Other heat-killing 
protocols using more prolonged exposure, higher temperatures, or both likely would 
have caused more pronounced changes in the R. equi ultrastructure.   Nevertheless, we 
observed that e-beam inactivation resulted in better maintenance of normal membrane 
integrity and structure.  These findings were considered important because structurally-
intact but non-replicating bacteria might be good candidates for mucosal vaccines. 
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Conclusion 
 
In this study we describe the e-beam irradiation doses required to completely 
inactivate 2 concentrations of R. equi without damage to their ultrastructure when 
irradiated using a 10-MeV, 18-kW linear accelerator. Electron-beam irradiation is an 
appropriate method for inactivating R. equi for in vitro studies of immune responses to 
inactivated bacteria as well as for potential use as a vaccine in foals against R. equi 
pneumonia. Studies evaluating the immunogenicity of e-beam inactivated R. equi 
administered in newborn foals are currently being performed by our laboratory. 
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